

(FILE 'HOME' ENTERED AT 06:41:03 ON 21 AUG 2007)

FILE 'REGISTRY' ENTERED AT 06:41:09 ON 21 AUG 2007


L1 STRUCTURE UPLOADED
L2 702 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 06:41:34 ON 21 AUG 2007

L3 34 S L2
L4 2 S US200!-522958/APPS
L5 33 S L3 NOT L4

FILE 'REGISTRY' ENTERED AT 06:43:08 ON 21 AUG 2007

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:esptasj11626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
 NEWS 2 MAY 01 New CAS web site launched
 NEWS 3 MAY 08 CA/CAPLUS Indian patent publication number format defined
 NEWS 4 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
 NEWS 5 MAY 21 BIOSIS reloaded and enhanced with archival data
 NEWS 6 MAY 21 TOXICENTER enhanced with BIOSIS reload
 NEWS 7 MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents
 NEWS 8 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese patents
 NEWS 9 JUN 27 CA/CAPLUS enhanced with pre-1967 CAS Registry Numbers
 NEWS 10 JUN 29 STN Viewer now available
 NEWS 11 JUN 29 STN Express, Version 8.2, now available
 NEWS 12 JUL 02 LEMBASS coverage updated
 NEWS 13 JUL 02 LMEEDLINE coverage updated
 NEWS 14 JUL 02 SCISEARCH enhanced with complete author names
 NEWS 15 JUL 02 CHEMCATS accession numbers revised
 NEWS 16 JUL 02 CA/CAPLUS enhanced with utility model patents from China
 NEWS 17 JUL 16 CAPLUS enhanced with French and German abstracts
 NEWS 18 JUL 18 CA/CAPLUS patent coverage enhanced
 NEWS 19 JUL 26 USPATTFULL/USPAT2 enhanced with IPC reclassification
 NEWS 20 JUL 30 USGENE now available on STN
 NEWS 21 AUG 06 CAS REGISTRY enhanced with new experimental property tags
 NEWS 22 AUG 06 BEILSTEIN updated with new compounds
 NEWS 23 AUG 06 FSTA enhanced with new thesaurus edition
 NEWS 24 AUG 13 CA/CAPLUS enhanced with additional kind codes for granted patents
 NEWS 25 AUG 20 CA/CAPLUS enhanced with CAS indexing in pre-1907 records

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V6.2,
 CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPCS For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

D

isolated ring systems:
containing 1: 10:

Match level:
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS

L1 STRUCTURE UPLOADED

=> # 11 sss full
 FULL SEARCH INITIATED 06:41:29 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 30626 TO ITERATE

100.0% PROCESSED 30626 ITERATIONS 702 ANSWERS
 SEARCH TIME: 00.00.01

L2 702 SEA SSS FUL L1

=> fil caplus
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 06:41:34 ON 21 AUG 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Aug 2007 VOL 147 ISS 9
 FILE LAST UPDATED: 20 Aug 2007 (20070820/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> # 12
 L3 34 L2

=> # s200:-522958/apps
 2 US200:-522958/AP
 0 US200:-522958/PRN
 L4 2 US200:-522958/APP9
 (US200:-522958/AP, PRN)

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 06:41:03 ON 21 AUG 2007

=> fil reg
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 06:41:09 ON 21 AUG 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by Infocem.

STRUCTURE FILE UPDATES: 20 AUG 2007 HIGHEST RN 945102-95-4
 DICTIONARY FILE UPDATES: 20 AUG 2007 HIGHEST RN 945102-95-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.


STN INFORMATION NOW CURRENT THROUGH JUNE 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> Uploading C:\Program Files\Stnexp\Queries\10522958-broad.str




ring nodes :
 1 2 3 4 5 6 7 8 9 10 11 12 13 14
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14
 exact/norm bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14

=> # 13 not 14
 L5 33 L3 NOT L4

=> d 15 tot bib abs hitstr

L5 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 2007.284227 CAPLUS Full-text
 DN 146:337892
 TI Regioselective process for preparing benzimidazole thiophenes
 IN Hornberger, Keith; Cheung, Mui; Pobanz, Mark Andrew; Emmitte, Kyle Allen;
 Kuntz, Kevin Wayne; Badiang, Jennifer Gabriel
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 31pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 PAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007030366	A1	20070315	WO 2006-US33793	20060828
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GO, GM, MW, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2005-714301P	P	20050906		
OS MARPAT 146:337892				
GI				



AB The present invention provides a process for preparing benzimidazole thiophene compds. of formula I (R1 = H, alkyl, alkenyl, etc.; Q1 = (R2)a(Y1)b(R2)cR3; a, b and c independently = 0 or 1 and at least one of a or b = 1; n = 0-3;

each Q2 independently = -(R2)aa(Y2)bb(R2)ccR4; or two adjacent Q2 together form a cyclic or heterocyclic ring optionally substituted; aa, bb and cc independently = 0 or 1; each Y1 and Y2 independently = O, CO, CO2, etc.; each R2 independently = alkylene, alkenylene and alkynylene; each R3 and R4 independently = H, halo, alkynyl, etc.; R5 = H, halo, cycloalkyl, etc.]. Thus, e.g., II was prepared by substitution of 2-bromo-4-((4-(methyloxy)phenyl)methyl)oxy)-1-nitrobenzene (preparation given) with Me 5-amino-3-((1R)-1-[2-(trifluoromethyl)phenyl]ethoxy)-2-thiophene carboxylate (preparation given) followed by nitro group reduction, cyclization with tri-Me orthoformate to form benzimidazole core, and deprotection. The processes of the instant invention produce the desired regioisomer via a more direct and efficient route, utilizing less resources and leading to a better yield. Intermediates used in the process are also claimed. Pharmaceutical compns. and therapeutic uses for I were described in prior patent (PCT Publication NO. WO04/014899, published 19 Feb. 2004).


IT 929279-57-2P 929279-59-4P

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (regioselective process for preparing benzimidazole thiophenes)

RN 929279-57-2 CAPLUS

CN 1H-Azepine-1-carboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]hexahydro-, 1,1-dimethylethyl ester, (4R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-59-4 CAPLUS

CN 1H-Azepine-1-carboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]hexahydro-, 1,1-dimethylethyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 929276-88-0

RL: RCT (Reactant); RACT (Reactant or reagent) (regioselective process for preparing benzimidazole thiophenes)

RN 929276-88-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinylcarbonyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 113387-85-2P 660869-51-2P 929040-09-5P

929040-11-9P 929040-14-2P 929040-18-6P

929040-21-1P 929040-24-4P 929040-25-5P

929040-26-6P 929040-28-8P 929040-32-4P

929040-33-5P 929040-37-9P 929040-38-0P

929040-40-4P 929040-41-5P 929095-16-5P

929095-38-5P 929095-39-6P 929095-41-0P

929095-42-1P 929095-43-2P 929095-44-3P

929095-48-7P 929095-49-8P 929095-50-1P

929095-51-2P 929095-55-6P 929095-56-7P

929095-59-0P 929095-62-5P 929095-63-6P

929095-64-9P 929095-67-0P 929095-71-4P

929095-74-5P 929095-76-0P 929095-76-1P

929095-77-2P 929095-78-3P 929095-79-4P

929276-44-8P 929276-47-1P 929276-48-2P

929276-91-5P 929277-03-2P 929277-09-8P

929277-10-1P 929277-11-2P 929277-38-3P

929277-58-7P 929277-63-0P 929278-32-0P

929278-54-6P 929278-56-8P 929278-73-9P

929278-78-4P 929278-81-9P 929278-92-1P

929278-95-5P 929278-97-7P 929279-04-8P

929279-06-1P 929279-08-3P 929279-10-7P

929279-12-9P 929279-13-0P 929279-15-2P

929279-17-4P 929279-19-6P 929279-21-0P

929279-23-2P 929279-35-6P 929279-37-8P

929279-39-0P 929279-41-4P 929279-43-6P

929279-45-8P 929279-47-0P 929279-49-2P

929279-55-0P 929279-61-8P 929279-66-3P

929279-68-5P 929279-70-9P 929279-72-1P

929279-74-3P 929279-76-5P 929279-78-7P

929279-79-8P 929279-81-2P 929279-83-4P

929280-05-2P 929280-03-5P 929280-06-8P

929280-08-0P 929280-10-4P 929280-12-6P

929280-14-6P 929280-16-0P 929280-18-2P

929280-20-6P 929280-28-4P 929280-30-8P

929280-32-0P 929280-34-2P 929280-36-4P

929280-38-6P 929280-40-0P 929280-42-2P

929280-44-4P 929280-46-6P 929280-51-3P

929280-54-6P 929280-56-8P 929280-62-6P

929280-64-8P 929280-66-0P 929280-68-2P

929280-70-6P 929280-72-8P 929280-76-2P

929280-78-4P 929280-84-2P 929280-86-4P

929280-88-6P 929280-90-0P 929280-92-2P

929280-94-4P 929280-96-6P 929280-98-8P

929281-00-5P 929281-05-0P 929281-07-2P

929281-09-4P 929281-11-8P 929281-13-0P

929281-15-2P 929281-17-4P 929281-19-6P

929281-21-0P 929281-23-2P 929281-25-4P

929281-27-6P 929281-29-8P 929281-31-2P

929281-33-4P 929281-36-7P 929281-38-9P

929281-40-3P 929281-42-5P 929281-44-7P

929281-46-9P 929281-48-1P 929281-50-5P

929281-55-0P 929281-57-2P 929281-68-5P

929281-70-9P 929281-72-1P 929281-73-2P

929281-74-3P 929281-75-4P 929281-76-5P

929281-79-7P 929281-79-8P 929281-83-4P

929281-84-5P 929281-85-1P 929281-86-4P

929281-87-6P 929281-88-7P 929281-89-8P

929281-90-9P 929281-91-0P 929281-92-1P

929281-93-2P 929281-94-3P 929281-95-4P

929281-96-5P 929281-97-6P 929281-98-7P

929281-99-8P 929282-00-9P 929282-01-0P

929282-02-1P 929282-03-2P 929282-04-3P

929282-05-4P 929282-06-5P 929282-07-6P

929282-08-7P 929282-09-8P 929282-10-9P

929282-11-0P 929282-12-1P 929282-13-2P

929282-14-3P 929282-15-4P 929282-16-5P

929282-17-6P 929282-18-7P 929282-19-8P

929282-20-9P 929282-21-0P 929282-22-1P

929282-23-2P 929282-24-3P 929282-25-4P

929282-26-5P 929282-27-6P 929282-28-7P

929282-29-8P 929282-30-9P 929282-31-0P

929282-32-1P 929282-33-2P 929282-34-3P

929282-35-4P 929282-36-5P 929282-37-6P

929282-38-7P 929282-39-8P 929282-40-9P

929282-41-0P 929282-42-1P 929282-43-2P

929282-44-3P 929282-45-4P 929282-46-5P

929282-47-6P 929282-48-7P 929282-49-8P

929282-50-9P 929282-51-0P 929282-52-1P

929282-53-2P 929282-54-3P 929282-55-4P

929282-56-5P 929282-57-6P 929282-58-7P

929282-59-8P 929282-60-9P 929282-61-0P

929282-62-1P 929282-63-2P 929282-64-3P

929282-65-4P 929282-66-5P 929282-67-6P

929282-68-7P 929282-69-8P 929282-70-9P

929282-71-0P 929282-72-1P 929282-73-2P

929282-74-3P 929282-75-4P 929282-76-5P

929282-77-6P 929282-78-7P 929282-79-8P

929282-80-9P 929282-81-0P 929282-82-1P

929282-83-2P 929282-84-3P 929282-85-4P

929282-86-5P 929282-87-6P 929282-88-7P

929282-89-8P 929282-90-9P 929282-91-0P

929282-92-1P 929282-93-2P 929282-94-3P

929282-95-4P 929282-96-5P 929282-97-6P

929282-98-7P 929282-99-8P 929283-00-9P

929283-01-0P 929283-02-1P 929283-03-2P

929283-04-3P 929283-05-4P 929283-06-5P

929283-07-6P 929283-08-7P 929283-09-8P


929283-10-9P 929283-11-0P 929283-12-1P

929283-13-2P 929283-14-3P 929283-15-4P

929283-16-5P 929283-17-6P 929283-18-7P

929283-19-8P 929283-20-9P 929283-21-0P


Absolute stereochemistry.



RN 929040-11-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-14-2 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 929040-09-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)






RN 929040-18-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)



Absolute stereochemistry.



RN 929040-21-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-28-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-32-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(chlorophenyl)ethoxy]-2-(chlorophenyl)ethoxy]-2-(chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-33-5 CAPLUS

RN 929040-24-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-25-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-[2-[(diphenylmethylene)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-26-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

CN 2-Thiophenecarboxamide, 5-[5-(5-bromo-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(chlorophenyl)ethoxy]-2-(chlorophenyl)ethoxy]-2-(chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-37-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[4-[(1R)-1-[2-(chlorophenyl)ethoxy]-2-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-38-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-40-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-41-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-16-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-38-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-39-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-41-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-42-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-43-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-44-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-48-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(ethenyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-49-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(1,2-dihydroxyethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-50-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-51-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-55-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 929095-63-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-hydroxymethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-66-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-67-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(6-hydroxy-


Absolute stereochemistry.



RN 929095-56-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-5-[6-[(trifluoromethyl)sulfonyloxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-59-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(dimethoxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-62-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-71-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methoxyphenyl)methoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-74-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-75-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-76-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-77-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-78-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-79-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-44-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-47-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-bromo-1H-benzimidazol-1-yl)-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 929276-48-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[(4-hydroxy-5-(methoxycarbonyl)-2-thienyl)-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 929276-91-5 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(difluoro-4-piperidinylmethyl)-1H-benzimidazol-1-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929276-90-4

CMP C26 H25 Cl F2 N4 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMP C2 H F3 O2



RN 929277-03-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(1-oxido-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-09-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2,3-dihydroxypropyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958


25 of 245



RN 929277-10-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[2-(1,3-dioxolan-2-yl)ethyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-11-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(3-oxopropyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-38-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10522958

27 of 245



RN 929278-32-0 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(3S)-3-piperidinylmethyl]-1H-benzimidazol-1-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 929278-31-9

CMP C26 H27 C1 N4 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMP C2 H F3 O2




RN 929278-54-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(4,4,4,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

10522958

26 of 245



RN 929277-58-7 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[(2-aminoethyl)methylamino]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 929277-57-6

CMP C24 H26 C1 N5 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMP C2 H F3 O2



RN 929277-69-0 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinylmethyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958

28 of 245


Absolute stereochemistry.



RN 929278-56-8 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(4,4,4,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-73-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[5-(methoxycarbonyl)-4-[2-(trimethylsilyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 929278-78-4 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[[1-(2-chlorophenyl)ethoxy]-5-[6-[[1-ethyl-4-piperidinyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.





RN 929278-81-9 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[1-[4-[[1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-83-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[1-[5-(aminocarbonyl)-4-[[1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-06-1 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[[1-(2-chlorophenyl)ethoxy]-5-[6-[3-hydroxy-1-(2-hydroxyethyl)propoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-08-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[6-[3-chloro-1-(2-chloroethyl)propoxy]-1H-benzimidazol-1-yl]-3-[[1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-10-7 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[1-(2-chlorophenyl)ethoxy]-5-[6-[[1-


RN 929278-95-5 CAPLUS
 CN 4-Morpholinecarboxylic acid, 2-[[[1-[4-[[1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 929278-97-7 CAPLUS
 CN 4-Morpholinecarboxylic acid, 2-[[[1-[5-(aminocarbonyl)-4-[[1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-04-9 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[[[1-(2-chlorophenyl)ethoxy]-5-[6-[3-[[1,1-dimethylethyl]diphenylsilyl]oxy]-1-[2-[[1,1-dimethylethyl]diphenylsilyl]oxy]propoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


cyclopentyl-4-piperidinyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-12-9 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[1-(2-chlorophenyl)ethoxy]-5-[6-[3-hydroxy-1-(2-hydroxyethyl)propoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-13-0 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[7-bromo-6-hydroxy-1H-benzimidazol-1-yl]-3-[[1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-15-2 CAPLUS

10522958

33 of 245

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-(5,7-dibromo-6-hydroxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-17-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[7-bromo-1-[4-[[1R]-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-19-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[[1R]-1-(2-chlorophenyl)ethoxy]-2-thienyl]-7-bromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958


34 of 245



RN 929279-21-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5,7-dibromo-1-[4-[[1R]-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-23-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[[1R]-1-(2-chlorophenyl)ethoxy]-2-thienyl]-5,7-dibromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958

35 of 245

RN 929279-35-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-bromo-6-[[4-methoxyphenyl)methoxy]-1H-benzimidazol-1-yl]-3-[[1R]-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-37-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5-bromo-6-hydroxy-1H-benzimidazol-1-yl)-3-[[1R]-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-39-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-bromo-1-[4-[[1R]-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958


36 of 245



RN 929279-41-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[[1R]-1-(2-chlorophenyl)ethoxy]-2-thienyl]-5-bromo-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-43-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[[1R]-1-(2-chlorophenyl)ethoxy]-2-thienyl]-5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-45-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-47-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-(6-hydroxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)



Absolute stereochemistry.



RN 929279-49-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-(6-hydroxy-1H-benzimidazol-1-yl)-3-[[1R]-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-68-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[4-[[1R]-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-70-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[[4-piperidinylsulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-72-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[[3-(hydroxypropyl)thio]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-55-0 CAPLUS

CN 1H-Azepine-1-carboxylic acid, hexahydro-4-[[1-[5-(methoxycarbonyl)-4-[[1R]-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-61-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[[cis-4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)cyclohexyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929279-66-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[4-[[1R]-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.



RN 929279-74-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[[3-(hydroxypropyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-76-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[[3-[(methylsulfonyl)oxy]propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929279-78-7 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[[1R]-1-(2-chlorophenyl)ethoxy]-5-[6-[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-79-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(sulfonylmethyl)-1H-benzimidazol-1-yl]-, 2-methyl ester, sodium salt (1:1) (CA INDEX NAME)


Absolute stereochemistry.



RN 929279-81-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylamino)sulfonylmethyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-06-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(2-hydroxyethyl)thio]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-08-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(2-hydroxyethyl)thio]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-10-4 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[(2-hydroxyethyl)sulfonylmethyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

RN 929279-83-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(aminomethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-00-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(1-piperazinylmethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)



Absolute stereochemistry.



RN 929280-03-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-piperazinylmethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-12-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(ethenylsulfonylmethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-14-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]difluoromethyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-16-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[difluoro(4-piperidinylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-18-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(cyanomethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-20-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(cyanomethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-28-4 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(trifluoromethyl)sulfonyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 929280-34-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]-1,2-dihydroxyethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-36-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl)carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-38-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl)carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-30-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl)ethenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



Absolute stereochemistry.



RN 929280-32-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl)ethenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-40-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl)ethenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-42-2 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[(1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl)ethenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-44-4 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-46-6 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[6-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-51-3 CAPLUS
 CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


CN 2-Thiophenecarboxylic acid, 5-(5-acetyl-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-64-8 CAPLUS
 CN 2-Thiophenecarboxamide, 5-(5-acetyl-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)



Absolute stereochemistry.



RN 929280-66-0 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-[(2E)-3-(dimethylamino)-1-oxo-2-propen-1-yl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 929280-54-6 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-56-8 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.




RN 929280-68-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(2-chloro-3-pyridinyl)methoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 929280-70-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(2-chloro-3-pyridinyl)methoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 929280-72-8 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(2-chloro-3-pyridinyl)methoxy]-5-[6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)



10522958 53 of 245


RN 929280-76-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-78-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-3-nitrophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-84-2 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 929280-86-4 CAPLUS

10522958 55 of 245


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2-propen-1-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929280-94-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2,3-dihydroxypropyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-96-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[2-(1,3-dioxolan-2-yl)ethyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-98-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2-


10522958 54 of 245

CN 2-Thiophenecarboxylic acid, 3-hydroxy-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)




RN 929280-88-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-chloro-3-[(1,1-dimethylethyl)dimethylsilyloxy]phenyl]ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929280-90-0 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929280-92-2 CAPLUS


10522958 56 of 245
oxoethyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-00-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(2-hydroxy-2-methoxyethyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929281-05-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-07-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-

10522958

57 of 245

(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl)methyl)sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-09-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl)sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-11-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl)sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958

59 of 245

RN 929281-19-6 CAPLUS

CN L-Valine, N-[3-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-21-0 CAPLUS

CN L-Alanine, N-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-23-2 CAPLUS

CN L-Alanine, N-[2-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958

58 of 245

RN 929281-13-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[[1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-15-2 CAPLUS

CN β-Alanine, N-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-17-4 CAPLUS

CN L-Alanine, N-[3-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958

60 of 245

RN 929281-25-4 CAPLUS

CN Carbamic acid, N-[2-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-27-6 CAPLUS

CN Carbamic acid, N-[2-[[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-29-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 929281-31-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-33-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-36-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-44-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-phenyl-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)



Absolute stereochemistry.



RN 929281-46-9 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[1-[5-(methoxycarbonyl)-4-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-38-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-thienyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-40-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-42-5 CAPLUS

RN 929281-48-1 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-50-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-55-0 CAPLUS

CN Imidodicarbonic acid, N-[6-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-3-pyridazinyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.

10522958


65 of 245



RN 929281-57-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(3,5-dimethyl-4-isoxazolyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-68-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-chloro-5-(2-(trimethylsilyl)ethoxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958

67 of 245

RN 929281-74-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[(3-methoxy-3-oxopropyl)thio]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-75-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[(3-methoxy-3-oxopropyl)sulfonyl]methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929281-76-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(aminosulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


10522958

66 of 245

RN 929281-70-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-chloro-5-hydroxy-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-72-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(4-amino-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-73-2 CAPLUS


CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-(dimethylamino)-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



10522958


68 of 245



RN 929281-78-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[(1R)-1-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 929281-79-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[(1R)-1-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 929281-83-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[(1R)-1-[[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

10522958

69 of 245


Absolute stereochemistry.



RN 929281-84-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 929288-39-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(2Z)-2-amino-2-(hydroxyimino)ethyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 929288-40-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(2Z)-2-[(acetyloxy)imino]-2-aminoethyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


10522958

70 of 245

benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 929288-41-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)cyclohexyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 929640-03-5P 929640-16-4P 929640-22-2P
 929640-23-3P 929640-27-7P 929640-29-9P
 929640-34-6P 929640-36-8P 929640-39-1P
 929640-42-6P 929640-17-0P 929640-18-1P
 929640-19-2P 929640-20-3P 929640-21-6P
 929640-22-7P 929640-23-8P 929640-40-9P
 929640-45-4P 929640-64-7P 929640-39-1P
 929640-40-4P 929640-41-5P 929640-42-6P
 929640-43-7P 929640-45-9P 929640-46-0P
 929640-49-3P 929640-50-6P 929640-51-7P
 929640-53-9P 929640-55-1P 929640-58-4P
 929640-60-9P 929640-62-0P 929640-64-2P
 929640-66-4P 929640-69-7P 929640-72-2P
 929640-74-4P 929640-76-6P 929640-77-7P
 929640-78-8P 929640-79-9P 929640-80-2P
 929640-82-4P 929640-83-5P 929640-84-6P
 929640-85-7P 929640-87-9P 929640-89-1P
 929640-92-6P 929640-94-8P 929640-96-0P
 929640-97-1P 929640-98-2P 929640-99-3P
 929640-00-5P 929640-02-1P 929640-04-3P

10522958


71 of 245

929277-05-4P 929277-06-5P 929277-07-6P
 929277-08-7P 929277-12-3P 929277-15-6P
 929277-14-9P 929277-21-4P 929277-24-7P
 929277-26-9P 929277-27-0P 929277-29-2P
 929277-32-7P 929277-34-9P 929277-36-1P
 929277-40-7P 929277-43-0P 929277-45-2P
 929277-47-4P 929277-50-9P 929277-52-1P
 929277-55-4P 929277-61-2P 929277-64-5P
 929277-67-8P 929277-71-4P 929277-72-5P
 929277-73-6P 929277-74-7P 929277-76-9P
 929277-78-1P 929277-79-2P 929277-81-6P
 929277-82-8P 929277-85-0P 929277-86-1P
 929277-87-2P 929277-88-1P 929277-90-7P
 929277-92-9P 929277-94-1P 929277-96-3P
 929277-98-5P 929278-00-2P 929278-02-4P
 929278-04-6P 929278-06-8P 929278-08-0P
 929278-10-4P 929278-12-6P 929278-14-8P
 929278-16-0P 929278-23-5P 929278-25-1P
 929278-27-3P 929278-29-5P 929278-34-2P
 RL: SPH (Synthetic preparation), PREP (Preparation)
 (regioselective process for preparing benzimidazole thiophenes)

RN 929040-03-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-16-4 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10522958

72 of 245

PAGE 1-A




PAGE 2-A



RN 929040-22-2 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-[2-[(1-methyl-4-piperidinyl)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-23-3 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-
 [(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-27-7 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-
 [(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-29-9 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.


RN 929040-39-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-42-6 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-methyl-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-17-0 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.





RN 929040-34-6 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-36-8 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-18-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929095-19-2 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-20-5 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10522958


77 of 245



RN 929095-21-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-22-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-23-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958


78 of 245



RN 929095-40-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-45-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-64-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958


79 of 245



RN 929276-39-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-40-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(6-chloro-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-41-5 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-

10522958

80 of 245

3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-42-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-43-7 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-45-9 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(2-chloro-4-pyrimidinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-46-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(2-chloro-4-pyrimidinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 929276-53-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-cyclopentyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-55-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-[7-bromo-6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-58-4 CAPLUS
CN Formic acid, compd. with 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5,7-dibromo-6-(4-piperidinyl)oxy]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide (1:1)




RN 929276-49-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-ethyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-50-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(3R)-3-piperidinylmethoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-51-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(2R)-2-morpholinylmethoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

(CA INDEX NAME)

CM 1

CRN 929276-57-3
CMF C25 H23 Br2 Cl N4 O3 S

Absolute stereochemistry.




CM 2

CRN 64-18-6
CMF C H2 O2

OH — CH — OH

RN 929276-60-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-62-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[3-

10522958

85 of 245

(dimethylamino)propoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-64-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-66-4 CAPLUS

CN Sulfamic acid, N,N-dimethyl-, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929276-69-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[4S]-hexahydro-1H-azepin-4-yl]oxy]-1H-

10522958

87 of 245



CM 2

CRN 76-05-1


CMP C2 H P3 O2



RN 929276-74-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[cis-4-aminocyclohexyl]oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-76-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[(4-piperidinylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958

86 of 245


benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929276-68-6

CMP C27 H27 P3 N4 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMP C2 H P3 O2



RN 929276-72-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[[[4R]-hexahydro-1H-azepin-4-yl]oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 929276-71-1

CMP C27 H27 P3 N4 O3 S

Absolute stereochemistry.

10522958


88 of 245



RN 929276-77-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[[[3-(dimethylamino)propyl]sulfonyl]methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929276-78-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[6-[[[methylamino)sulfonyl]methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-79-9 CAPLUS


CN 2-Thiophenecarboxamide, 5-[6-[[[methylsulfonyl]amino]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10522958 93 of 245

CN 2-Thiophenecarboxamide, 5-[6-[(4-amino-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 929276-97-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929276-98-2 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[4-(ethylsulfonyl)-1-piperazinyl]methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958 95 of 245

RN 929277-02-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[2-(1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

RN 929277-04-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[(1,2-dihydro-2-oxo-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.


10522958 94 of 245



RN 929276-99-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-methylethyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 929277-00-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




10522958 96 of 245



RN 929277-05-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[2-(1-piperazinyl)-4-pyrimidinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

RN 929277-06-5 CAPLUS

10522958

97 of 245


CN 2-Thiophenecarboxamide, 3-[(2-chloro-3-pyridinyl)methoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)



RN 929277-07-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(3-amino-2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-08-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chloro-3-hydroxyphenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




10522958

99 of 245

RN 929277-21-4 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-24-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-26-9 CAPLUS

CN Ethanesulfonic acid, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)

Absolute stereochemistry.




10522958

98 of 245

RN 929277-12-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[2-[(methylsulfonyl)ethyl]amino]ethyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-15-6 CAPLUS

CN 2-Propanesulfonic acid, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-18-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(phenylsulfonyl)oxy]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




10522958

100 of 245

RN 929277-27-0 CAPLUS

CN 1-Propanesulfonic acid, 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-29-2 CAPLUS


CN Formic acid, compd. with 1-[5-(aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-6-yl N-[3-(dimethylamino)propyl]-N-methylsulfamate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-28-1

CMP C27 H30 F3 N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMP C H2 O2

O=CH-OH

10522958


101 of 245

RN 929277-32-7 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[6-(difluoro(4-piperidinylsulfonyl)methyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-31-6
 CMP C27 H25 F5 N4 O4 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMP C2 H F3 O2



RN 929277-34-9 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)carbonyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




10522958

102 of 245

RN 929277-36-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[difluoro(1-methylethyl)-4-piperidinylmethyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-40-7 CAPLUS
 CN β-Alanine, N-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 929277-39-4
 CMP C24 H23 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMP C2 H F3 O2

10522958

103 of 245




RN 929277-43-0 CAPLUS
 CN L-Alanine, N-[3-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-42-9
 CMP C26 H27 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMP C2 H F3 O2



RN 929277-45-2 CAPLUS
 CN L-Valine, N-[3-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]propyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 929277-44-1
 CMP C28 H31 Cl N4 O4 S

Absolute stereochemistry.

10522958

104 of 245



CM 2

CRN 76-05-1
 CMP C2 H F3 O2




RN 929277-47-4 CAPLUS
 CN L-Alanine, N-[[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-46-3
 CMP C24 H23 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

10522958
CMP C2 H F3 O2




RN 929277-50-9 CAPLUS
CN L-Alanine, N-[2-[[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-6-yl]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 929277-49-6
CMP C25 H25 Cl N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 929277-52-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[2-(methylsulfonyl)ethyl]amino]methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958
CM 1
CRN 929277-60-1
CMP C26 H30 Cl N5 O2 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 929277-64-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[1-(2-hydroxyethyl)-4-piperidinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-67-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

10522958
106 of 245




RN 929277-55-4 CAPLUS
CN 2-Thiophenecarboxamide, 5-[6-[[[(2-aminoethyl)amino]methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 929277-54-3
CMP C23 H24 Cl N5 O2 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMP C2 H F3 O2



RN 929277-61-2 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[[[2-(dimethylamino)ethyl]methylamino]methyl]-1H-benzimidazol-1-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


10522958
108 of 245

Absolute stereochemistry.




RN 929277-71-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-72-5 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(2-thienyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-73-6 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-74-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(4-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)



Absolute stereochemistry.



RN 929277-76-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(5-phenyl-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-83-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(3,5-dimethyl-4-isoxazolyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-85-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-(6-chloro-5-hydroxy-1H-benzimidazol-1-yl)-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-86-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-amino-2-methyl-3-pyridinyl)-1H-

RN 929277-78-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrrol-2-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-79-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-81-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(6-amino-3-pyridazinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-87-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-imidazol-5-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929277-88-3 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-(2-amino-5-pyrimidinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-90-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-[2-(dimethylamino)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929277-92-9 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-[2-(methylamino)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-94-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-[2-methyl-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.


yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-02-4 CAPLUS
CN Benzenepropanoic acid, 3-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-04-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(methylamino)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-96-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-(dimethylamino)-1-piperidinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929277-98-5 CAPLUS
CN 2-Thiophenecarboxamide, 5-[6-[(aminosulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-00-2 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(3-amino-4-methoxyphenyl)-1H-benzimidazol-1-yl]-




RN 929278-06-8 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(6-methoxy-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929278-08-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-[5-(6-amino-3-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



10522958 117 of 245

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-12-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[6-(4-amino-1-piperidinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-14-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(methyl(1-methyl-4-piperidinyl)amino)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.

10522958 119 of 245


Absolute stereochemistry.



RN 929278-17-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(trans-4-(dimethylamino)cyclohexyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-29-5 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(trans-4-[[2-(methylsulfonyl)ethyl]amino)cyclohexyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-34-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1S)-1-methyl-3-piperidinyl]methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


10522958 118 of 245



RN 929278-16-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1R)-1-[(3R)-3-piperidinyl]ethoxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929278-23-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[6-(trans-4-aminocyclohexyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929278-25-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[6-(cis-4-aminocyclohexyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-chlorophenyl)ethoxy]- (CA INDEX NAME)

10522958 120 of 245

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RS FORMAT

L5 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2007:283577 CAPLUS [Full-text](#)

DN 146:337898

TI Preparation of benzimidazolyl thiophene derivatives as PLK modulators
IN Cheung, Mui; Badiang, Jennifer Gabriel; Donaldson, Kelly Horne; Rheault, Tara Renae

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 80pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI NO 2007030359	A1	20070315	WO 2006-US33616	20060828
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MD, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GM, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2005-714303P P 20050906

OI




AB The present invention provides 5-heteroaryl substituted benzimidazole thiophene derivs., pharmaceutical compns. containing the same, processes for preparing the same and their use as pharmaceutical agents. For example, 1 was provided in a multi-step synthesis starting from the reaction of Me 3-hydroxy-5-nitro-2-thiophenecarboxylate with (1R)-1-[2-(trifluoromethyl)phenyl]ethanol. The prepared title compds. were tested for inhibition of PLK-1 (polo-like kinase 1), methylene blue cell growth inhibition, cell-titer glo cell growth inhibition and pharmacokinetics.

IT 660869-61-4P 660869-62-5P 660869-69-2P
660869-93-2P 929040-03-9P, 5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
929040-16-4P, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
929040-22-2P, 5-[5-[2-[(1-methyl-4-piperidinyl)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
929040-23-3P, 5-[5-[2-Amino-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
929040-27-7P, 5-[5-[1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-[[1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide
929040-29-9P, 3-[[1R)-1-[2-(chlorophenyl)ethyl]oxy]-5-[5-[6-[(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide
929040-36-8P 929040-39-1P, 3-[[1R)-1-[2-(chlorophenyl)ethyl]oxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-2-thiophenecarboxamide
929040-42-6P, 3-[[1R)-1-[2-(chlorophenyl)ethyl]oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazolyl thiophene derivs. as Polo-like kinases (PLK) modulators)


RN 660869-61-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)




RN 660869-62-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)




RN 660869-69-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-methoxy-5-[3-(2-oxo-1-pyrrolidinyl)propoxy]-1H-benzimidazol-1-yl]-3-[2-(trifluoromethyl)phenyl]methoxy)- (CA INDEX NAME)



RN 660869-93-2 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 1-[5-(aminocarbonyl)-4-[[2-(trifluoromethyl)phenyl]methoxy]-2-thienyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (CA INDEX NAME)



RN 929040-03-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-16-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 929040-22-2 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-[2-[(1-methyl-4-piperidinyl)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[[1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-23-3 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-27-7 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-29-9 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-36-8 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-39-1 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-42-6 CAPLUS
 CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



IT 929040-43-7P 929040-44-8P 929040-45-9P
 929040-46-0P 929040-47-1P 929040-48-2P
 929040-49-3P 929040-50-6F 929040-51-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzimidazolyl thiophene deriva. as Polo-like kinases (PLK) modulators)

RN 929040-43-7 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929040-44-8 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-

benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 929040-45-9 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[5-[2-[(1-methyl-4-piperidinyl)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-46-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 929040-47-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1S)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

RN 929040-50-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-[3-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 929040-51-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-methyl-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 929040-09-5P, Methyl 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxylate
 929040-11-9P 929040-14-2P 929040-18-6P,
 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide
 929040-21-1P, 5-[5-(2-fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-thiophenecarboxamide
 929040-24-4P, Methyl 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-thiophenecarboxylate
 929040-25-5P, Methyl 5-[5-[2-[(diphenylmethylidene)amino]-4-pyridinyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-thiophenecarboxylate



RN 929040-48-2 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-[(1-methyl-4-piperidinyl)amino]-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-49-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1S)-1-(2-chlorophenyl)ethoxy]-5-[5-[6-(1-piperazinyl)-3-pyridinyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




929040-26-6P, Methyl 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxylate
 929040-28-8P, Methyl 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxylate
 929040-32-4P 929040-33-5P,
 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(chlorophenyl)ethyl]oxy]thiophene-2-carboxamide 929040-34-6P,
 3-[(1R)-1-(2-chlorophenyl)ethyl]oxy]-5-[5-(6-fluoropyridin-3-yl)-1H-benzimidazol-1-yl]thiophene-2-carboxamide 929040-37-5P
 929040-38-0P, 1,1-Dimethylethyl 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethyl]oxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-1-piperazinecarboxylate 929040-40-4P
 929040-41-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzimidazolyl thiophene derivs. as Polo-like kinases (PLK) modulators)

RN 929040-09-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-11-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(methoxycarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-14-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-{1-[(5-aminocarbonyl)-4-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-18-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-21-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(2-fluoro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-24-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-chloro-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-25-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-[(diphenylmethylene)amino]-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-26-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(2-amino-4-pyridinyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-28-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-(1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-32-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(chlorophenyl)ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-33-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(chlorophenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-34-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-[2-(chlorophenyl)ethoxy]-5-[5-(6-fluoro-3-pyridinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-37-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[4-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(methoxycarbonyl)-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-38-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1-[5-(aminocarbonyl)-4-[(1R)-1-(2-chlorophenyl)ethoxy]-2-thienyl]-1H-benzimidazol-5-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-40-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929040-41-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[5-[1-(4-ethyl-1-piperazinyl)propyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2007:282094 CAPLUS Full-text

DN 146:337890

TI Preparation of thiophenyl benzimidazole derivatives for treatment of conditions mediated by polo-like kinases

IN Cheung, Mui, Emmitte, Kyle Allen; Salovich, James Michael

PA Smithkline Beecham Corp., USA

SO PCT Int. Appl., 107pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007030361	A2	20070315	WO 2006-US33683	20060828
MO 2007030361	A3	20070531		


M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GR, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SI, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MN, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2005-714337P P 20050906

US 2006-786244P P 20060327

GI



AB Eight thiophenyl benzimidazole derivs. and pharmaceutically acceptable salts and solvates thereof were prepared for the treatment of conditions mediated by polo-like kinases (PLK). For example, N-methylpiperazine was treated with Me 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethyl]oxythiophene-2-carboxylate (preparation given) at 60 °C for 18 h in dioxane to give an intermediate which was further reacted with ammonia in MeOH at 80 °C for 40 h in a sealed flask to give I as a final product. I showed superior enzyme and cell potency in PLK1 enzyme assay and methylene blue cell proliferation assay in multiple cell lines. I also had superior protein binding in human serum by equilibrium dialysis assay. On the other hand, I showed good solubility in 0.05 M pH 7.4 phosphate buffer.

IT 929095-16-9P 929095-17-0P 929095-18-1P

929095-19-2P 929095-20-5P 929095-21-6P

929095-22-7P 929095-23-9P 929095-26-1P

929095-27-2P 929095-28-3P 929095-29-4P

929095-30-7P 929095-31-8P 929095-32-9P

929095-33-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of thiophenyl benzimidazole derivs. for treatment of conditions mediated by polo-like kinases)

RN 929095-16-9 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-17-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-18-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-19-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-20-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-26-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-27-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-28-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-21-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-22-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-23-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-29-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-30-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-31-8 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(1-methyl-4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.

10522958


145 of 245



RN 929095-32-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinyl)oxy]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-33-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 660869-56-7 660869-51-4 660869-62-5

660869-71-6 660869-79-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(preparation of thiophenyl benzimidazole derivs. for treatment of conditions mediated by polo-like kinases)


10522958

147 of 245



RN 660869-79-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(4-piperidinyl)methoxy]-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



IT 660870-07-5P 929095-38-5P 929095-35-6P

929095-40-5P 929095-41-0P 929095-42-1P

929095-43-2P 929095-44-3P 929095-45-4P

929095-46-5P 929095-47-6P 929095-48-7P

929095-49-8P 929095-50-1P 929095-51-2P

929095-54-5P 929095-55-6P 929095-56-7P

929095-59-0P 929095-62-8P 929095-63-6P

929095-64-7P 929095-66-9P 929095-67-0P

929095-71-6P 929095-74-2P 929095-75-3P

929095-76-1P 929095-77-2P 929095-78-3P

929095-79-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of thiophenyl benzimidazole derivs. for treatment of

conditions mediated by polo-like kinases)

RN 660870-07-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-bromo-1H-benzimidazol-1-yl]-3-hydroxy-, methyl ester (CA INDEX NAME)

10522958

146 of 245


RN 660869-56-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-(methylsulfonyl)-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 660869-61-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)



RN 660869-62-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[1-(2-(trifluoromethyl)phenyl)ethoxy]- (CA INDEX NAME)




RN 660869-71-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-methoxy-6-[2-(4-methyl-1-piperazinyl)ethoxy]-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)

10522958


148 of 245



RN 929095-38-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-39-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-40-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-41-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-42-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-43-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-47-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-bromo-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-48-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-ethenyl-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-49-8 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(1,2-dihydroxyethyl)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-44-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-45-4 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylthio)methyl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-46-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(methylsulfonyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-50-1 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-51-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-54-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-(methoxymethoxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958


153 of 245



RN 929095-55-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy)-3-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy)-1H-benzimidazol-1-yl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-56-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy)-5-[[6-[[trifluoromethyl)sulfonyl]oxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-59-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[6-(dimethoxymethyl)-1H-benzimidazol-1-yl]-3-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958


155 of 245



RN 929095-66-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-((1R)-1-(2-(chlorophenyl)ethoxy)-5-[[4-methyl-1-piperazinyl)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-67-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-((1R)-1-(2-(chlorophenyl)ethoxy)-5-(6-hydroxy-1H-benzimidazol-1-yl)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-71-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-((1R)-1-(2-(chlorophenyl)ethoxy)-5-[[4-methoxyphenyl)methoxy]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958


154 of 245



RN 929095-62-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-((1R)-1-(2-(chlorophenyl)ethoxy)-5-[[6-[[2,2-dimethyl-1-oxopropoxy)methyl]-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-63-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-((1R)-1-(2-(chlorophenyl)ethoxy)-5-[[6-(hydroxymethyl)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 929095-64-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[6-(chloromethyl)-1H-benzimidazol-1-yl]-3-((1R)-1-(2-(chlorophenyl)ethoxy)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

10522958


156 of 245



RN 929095-74-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[1-[[5-(methoxycarbonyl)-4-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy)-2-thienyl)-1H-benzimidazol-6-yl]oxy]-1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-75-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[[6-(4-piperidinyloxy)-1H-benzimidazol-1-yl]-3-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy)-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 929095-76-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[1-[[4-((1R)-1-(2-(chlorophenyl)ethoxy)-5-

10522958

157 of 245

(methoxycarbonyl)-2-thienyl)-1H-benzimidazol-6-ylloxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-77-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(4-piperidinylloxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 929095-78-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-[6-[(1-methyl-4-piperidinylloxy)-1H-benzimidazol-1-yl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



10522958


159 of 245

IT 660868-91-7

RL: DMA (Drug mechanism of action), PAC (Pharmacological activity), THU (Therapeutic use), BIOL (Biological study), USES (Uses)
(in vitro biol. activity of a small-mol. inhibitor of polo-like kinase 1)

RN 660868-91-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 5 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1190032 CAPLUS Full-text

DN 146:54723

TI 5-(1H-Benzimidazol-1-yl)-3-alkoxy-2-thiophenecarbonitriles as potent, selective, inhibitors of IKK-ε kinase

AU Bamborough, Paul; Christopher, John A.; Cutler, Geoffrey J.; Dickson, Marion C.; Mellor, Geoffrey W.; Morey, James V.; Patel, Champa B.; Shewchuk, Lisa M.

CS Medicines Research Centre, GlaxoSmithKline R & D, Hertfordshire, SG1 2NY, UK

SO Bioorganic & Medicinal Chemistry Letters (2006), 16(24), 6236-6240

CODEN: BMCL68; ISSN: 0960-894X


PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 146:54723

GI



I


10522958

158 of 245

RN 929095-79-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-[(1-methyl-4-piperidinylloxy)-1H-benzimidazol-1-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



LS ANSWER 4 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:181791 CAPLUS Full-text

DN 146:414432

TI In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1

AU Lansing, Timothy J.; McConnell, Randy T.; Duckett, Derek R.; Spehar, Glenn M.; Knick, Victoria B.; Hassler, Daniel F.; Noro, Nobuhiro; Furuta, Masaaki; Emmitte, Kyle A.; Gilmer, Tona M.; Mook, Robert A., Jr.; Cheung, Mui

CS Oncology Biology, GlaxoSmithKline, Research Triangle Park, NC, USA

SO Molecular Cancer Therapeutics (2007), 6(2), 450-459

CODEN: MCTOCP; ISSN: 1535-7163

PB American Association for Cancer Research

DT Journal

LA English

AB Polo-like kinase 1 (PLK1) plays key roles in the regulation of mitotic progression, including mitotic entry, spindle formation, chromosome segregation, and cytokinesis. PLK1 expression and activity are strongly linked to proliferating cells. Many studies have shown that PLK1 expression is elevated in a variety of tumors, and high expression often correlates with poor prognosis. Using a variety of methods, including small-mol. inhibition of PLK1 function and/or activity, apoptosis in cancer cell lines, cell cycle arrest in normal cell lines, and antitumor activity in vivo have been observed. In the present study, the authors have examined the in vitro biol. activity of a novel and selective thiophene benzimidazole ATP-competitive inhibitor of PLK1 and PLK3 (5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)benzylloxy]thiophene-2-carboxamide, called compound 1). Compound 1 has low nanomolar activity against the PLK1 and PLK3 enzymes and potentially inhibits the proliferation of a wide variety of tumor cell lines. In the lung adenocarcinoma cell line H460, compound 1 induces a transient G2-M arrest, mitotic spindle defects, and a multinucleate phenotype resulting in apoptosis, whereas normal human diploid fibroblasts arrest in G2-M and show little apoptosis. The authors also describe a cellular mechanistic assay that was developed to identify potent intracellular inhibitors of PLK1. In addition to its potential as a therapeutic agent for treating cancer, compound 1 is also a useful tool mol. for further investigation of the biol. functions of PLK1 and PLK3.

10522958


160 of 245

AB The identification and hit-to-lead exploration of a novel, potent and selective series of substituted benzimidazole-thiophene carbonitrile inhibitors of IKK-ε kinase is described. Compound 12e (I) was identified with an IKK-ε enzyme potency of pIC50 7.4, and has a highly encouraging wider selectivity profile, including selectivity within the IKK kinase family.

IT 916985-24-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(benzimidazolyl alkoxy thiophenecarbonitriles as inhibitors of IKK-ε kinase)

RN 916985-24-5 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-hydroxy- (CA INDEX NAME)



IT 660869-82-9P 862812-86-OP 862812-89-3P

862812-94-OP 862812-98-4P 862813-04-5P


862813-12-5P 862813-17-OP 916985-36-9P

916985-39-2P 916985-41-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzimidazolyl alkoxy thiophenecarbonitriles as inhibitors of IKK-ε kinase)

RN 660869-82-9 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)




RN 862812-86-0 CAPLUS

CN 2-Thiophenecarbonitrile, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)

10522958


161 of 245

Absolute stereochemistry.




RN 862812-89-3 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[(1H-benzimidazol-1-yl)-3-(phenylmethoxy)]- (CA INDEX NAME)



RN 862812-94-0 CAPLUS

CN 2-Thiophenecarbonitrile, 5-[6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 862812-98-4 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[2-(methylsulfonyl)phenyl]methoxy]- (CA INDEX NAME)


10522958

163 of 245




RN 916985-36-9 CAPLUS

CN 2-Thiophenecarbonitrile, 3-(cyclopropylmethoxy)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)



RN 916985-39-2 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 916985-41-6 CAPLUS

CN Benzamide, 4-[[[2-cyano-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-thienyl]oxyl]methyl]- (CA INDEX NAME)


10522958

162 of 245



RN 862813-04-5 CAPLUS


CN 2-Thiophenecarbonitrile, 5-[5-(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)



RN 862813-12-5 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[1R]-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-17-0 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)

10522958

164 of 245



IT 660868-39-3 660870-60-0 862813-19-2


862813-28-3 862813-38-5 916985-21-2

916985-22-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzimidazolyl alkoxy thiophenecarbonitriles as inhibitors of IKK-ε kinase)


RN 660868-39-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-(1H-benzimidazol-1-yl)-3-[(4-methylphenyl)methoxy]- (CA INDEX NAME)



RN 660870-60-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 862813-19-2 CAPLUS

10522958

165 of 245


CN 2-Thiophenecarbonitrile, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-
[(tetrahydro-2-furanyl)methoxy]) - (CA INDEX NAME)



RN 862813-28-3 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl) - (CA INDEX NAME)

Absolute stereochemistry.



RN 862813-38-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-
[(tetrahydro-2-furanyl)methoxy] - (CA INDEX NAME)




RN 916985-21-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[4-(methylsulfonyl)phenyl]methoxy] - (CA INDEX NAME)


10522958

166 of 245



RN 916985-22-3 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[[4-(methylsulfonyl)phenyl]methoxy] - (CA INDEX NAME)




IT 916985-25-6P 916985-26-7P 916985-27-8P

RL: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent)
(benzimidazolyl alkoxy thiophenecarbonitriles as inhibitors of IKK-ε kinase)

RN 916985-25-6 CAPLUS

CN 2-Thiophenecarbonitrile, 3-hydroxy-5-(6-methoxy-5-(2-(4-morpholinyl)ethoxy)-1H-benzimidazol-1-yl) - (CA INDEX NAME)




RN 916985-26-7 CAPLUS

10522958


167 of 245

CN 2-Thiophenecarbonitrile, 3-hydroxy-5-[(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl] - (CA INDEX NAME)



RN 916985-27-8 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-hydroxy - (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1190017 CAPLUS [Full-text](#)

DN 146:74597

TI Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists

AU Bell, Ian M.; Bednar, Rodney A.; Fay, John F.; Gallicchio, Steven N.; Hochman, Jerome H.; McMasters, Daniel R.; Miller-Stein, Cynthia; Moore, Eric L.; Mosser, Scott D.; Pudvah, Nicole T.; Quigley, Amy G.; Salvatore, Christopher A.; Stump, Craig A.; Theberge, Cory R.; Wong, Bradley K.; Zartman, C. Blair; Zhang, Xu-Fang; Kane, Stefanie A.; Graham, Samuel L.; Vacca, Joseph P.; Williams, Theresa M.

CS Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA

SO Bioorganic & Medicinal Chemistry Letters (2006), 16(24), 6165-6169

CODEN: BMCL88; ISSN: 0960-894X

Elsevier Ltd.


Journal

English

GI

10522958

168 of 245



I

AB A rapid analog approach to identification of spirohydantoin-based CGRP antagonists provided novel, low mol. weight leads. Modification of these leads afforded a series of nanomolar benzimidazolinone-based CGRP receptor antagonists. The oral bioavailability of these antagonists was inversely correlated with polar surface area, suggesting that membrane permeability was a key limitation to absorption. Optimization provided compound 12 (I), a potent CGRP receptor antagonist (K_i = 21 nM) with good oral bioavailability in three species.


IT 916918-57-5

RL: PAC (Pharmacological activity), PKT (Pharmacokinetics), PRP (Properties), THU (Therapeutic use), BIOL (Biological study), USES (Uses)
(orally bioavailable spirohydantoin CGRP receptor antagonists)

RN 916918-57-5 CAPLUS

CN 1H-Benzimidazole-1-acetamide, N-[(2'R)-1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl]-2,3-dihydro-2-oxo-3-(tetrahydro-1,1-dioxido-3-thienyl) - (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1172142 CAPLUS [Full-text](#)

DN 146:55726

TI Bayesian-regularized genetic neural networks applied to the modeling of

non-peptide antagonists for the human luteinizing hormone-releasing hormone receptor.

AB Fernandez, Michael; Caballero, Julio

CS Molecular Modeling Group, Center for Biotechnological Studies, University of Matanzas, Matanzas, 44740, Cuba

SO Journal of Molecular Graphics & Modelling (2006), 25(4), 410-422

CODEN: JMGMPF; ISSN: 1093-3263

PB Elsevier Inc.

DT Journal

LA English

AB Bayesian-regularized genetic neural networks (BRGNNs) were used to model the binding affinity (C50) for 128 non-peptide antagonists for the human LH-releasing hormone (LHRH) receptor using 2D spatial autocorrelation vectors. As a preliminary step, a linear dependence was established by multiple linear regression (MLR) approach, selecting the relevant descriptors by genetic algorithm (GA) feature selection. The linear model showed to fit the training set (N = 102) with R² = 0.746, meanwhile BRGNN exhibited a higher value of R² = 0.871. Beyond the improvement of training set fitting, the BRGNN model overcame the linear one by being able to describe 85% of test set (N = 26) variance in comparison with 73% the MLR model. The authors' non-linear QSAR model illustrates the importance of an adequate distribution of atomic properties represented in topol. frames and reveals the electronegativities, masses and polarizabilities as the most influencing atomic properties in the structures of the heterocycles under anal. for having an appropriate LHRH antagonistic activity. Furthermore, the ability of the non-linear selected variables for differentiating the data was evidenced when total data set was well distributed in a Kohonen self-organizing map (SOM).


IT 917017-69-7

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(Bayesian-regularized genetic neural networks applied to modeling binding affinity for non-peptide antagonists for human LH-RH receptor using 2D spatial autocorrelation vectors)

RN 917017-69-7 CAPLUS

CN 1H-Benzimidazole-5-sulfonamide, 2-ethoxy-N-[(4-fluorophenyl)methyl]-1-(3-thienyl)- (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2006:971442 CAPLUS [Full-text](#)


DN 145:505375

TI 2-Aminopyrimidine-4,6-diol as an efficient ligand for solvent-free copper-catalyzed N-arylations of imidazoles with aryl and heteroaryl halides

AU Xie, Ye-Xiang; Pi, Shao-Peng; Wang, Jian; Yin, Du-Lin; Li, Jin-Heng


CS Key Laboratory of Chemical Biology & Traditional Chinese Medicine Research (Ministry of Education), College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha, 410081, Peop. Rep. China

SO Journal of Organic Chemistry (2006), 71(21), 8324-8327




RN 884068-82-0 CAPLUS

CN 1H-Benzimidazole, 1-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 892493-38-4 CAPLUS

CN 1H-Benzimidazole, 1-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2005:823697 CAPLUS [Full-text](#)

DN 143:229853

TI Preparation of benzimidazolyl substituted thiophene derivatives with activity against IKK3

IN Bamborough, Paul; Morey, James Vaughan

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005075465	A1	20050818	WO 2005-EP1432	20050207

M: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BM, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RM: BM, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, BU, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG

EP 1720864 A1 20061115 EP 2005-707356 20050207

CODEN: JOCEAH; ISSN: 0022-3263

PB American Chemical Society

DT Journal

LA English

OS CASREACT 145:505375

AB Solvent-free copper-catalyzed N-arylations of imidazoles with aryl and heteroaryl halides have been demonstrated. In the presence of CuBr, 2-aminopyrimidine-4,6-diol, and TBAF (n-Bu₄NF), a variety of imidazoles underwent the N-arylation reaction with aryl and heteroaryl halides smoothly in moderate to excellent yields. Noteworthy is that the reaction was conducted under solvent-free conditions.


IT 884068-82-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(Preparation of N-arylimidazoles and N-arylbenzimidazoles via copper-aminopyrimidinol-catalyzed N-arylation with imidazoles or benzimidazoles with aryl halides under solvent-free conditions)

RN 884068-82-0 CAPLUS

CN 1H-Benzimidazole, 1-(2-thienyl)- (9CI) (CA INDEX NAME)



RE.CNT 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2006:398159 CAPLUS [Full-text](#)

DN 145:83268

TI CuI catalyzed C-N bond forming reactions between aryl/heteroaryl bromides and imidazoles in [Bmim]BF₄

AU Lv, Xin; Wang, Zhiming; Bao, Weiliang

CS Zhejiang University, Department of Chemistry, Zhejiang, 310028, Peop. Rep. China

SO Tetrahedron (2006), 62(20), 4756-4761

CODEN: TETRAH; ISSN: 0040-4020

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 145:83268

AB By using CuI as the catalyst and L-Proline as the ligand, the Ullmann-type coupling reactions of aryl/heteroaryl bromides and imidazoles in [Bmim]BF₄ at 105-115 °C gave the corresponding N-arylimidazoles/H- heteroarylimidazoles in good yields. The system offers a convenient, recyclable, and environmentally benign method for these coupling reactions.

IT 312959-35-6P 884068-82-0P 892493-38-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(copper catalyzed Ullmann-type coupling reaction of aryl/heteroaryl bromides and imidazoles in ionic liqs.)

RN 312959-35-6 CAPLUS

CN 1H-Benzimidazole, 1-(3-thienyl)- (9CI) (CA INDEX NAME)

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV

JP 2007522142 T 20070809 JP 2006-551827 20050207


US 2007149519 A1 20070628 US 2006-597828 20060809

PRAI GB 2004-2809 A 20040209 20050207

MO 2005-EP1432 W 20050207

OS MARPAT 143:229853

GI



AB The title compds. I [n = 0-4; R₁ = H, halo, XaYbZ (wherein X = O, CONH, a = 0-1; Y = alkylene; b = 0-1; Z = OH, alkyl, haloalkyl, etc.); R₂ = (X₁)c(Y₁)dZ₁ (X₁ = alkylene; c = 0-1; Y₁ = O; d = 0-1; Z₁ = H, aryl, heteroaryl, etc.)] which are potentially useful in the treatment of diseases associated with inappropriate I-kappa-B kinase-3 (IKK3) (also known as I-kappa-B kinase epsilon (IKKε) or inducible I-kappa B kinase (IKKi)) activity, were prepared thus, treating a solution of 5,6-bis(methoxy)-1H-benzimidazol-1-yl]-3-[(4-(hydroxymethyl)phenyl)methyl]oxy]-2-thiophenecarbonitrile and pyridine in CH₂Cl₂ with trifluoroacetic anhydride at -10°C afforded II which showed pIC₅₀ of >6.0 when tested in IKK3 assay. The pharmaceutical composition comprising the compound I is disclosed.


IT 660868-54-2P 660869-82-9P 862812-84-3P 862812-86-0P 862812-89-3P 862812-92-8P 862812-94-0P 862812-96-2P 862812-98-4P 862813-00-1P 862813-02-3P 862813-04-5P 862813-06-7P 862813-08-9P 862813-10-3P 862813-12-5P 862813-14-7P 862813-15-8P 862813-16-9P 862813-17-0P 862813-18-1P 862813-19-2P 862813-20-5P 862813-21-6P 862813-22-7P 862813-23-8P 862813-24-9P 862813-25-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzimidazolyl substituted thiophene derivs. with activity against IKK3)

RN 660868-54-2 CAPLUS


CN 2-Thiophenecarbonitrile, 5-[(1H-benzimidazol-1-yl)-3-[(2-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 660869-82-9 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)




RN 862812-84-8 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(4-(hydroxymethyl)phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 862812-86-0 CAPLUS
CN 2-Thiophenecarbonitrile, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 862812-89-3 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 862812-92-8 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1-methyl-1H-benzotriazol-6-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 862812-94-0 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)




RN 862812-96-2 CAPLUS
CN 2-Thiophenecarbonitrile, 3-[(2,5-difluorophenyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 862812-98-4 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(methylsulfonyl)phenyl)methoxy]- (CA INDEX NAME)




RN 862813-00-1 CAPLUS
CN 2-Thiophenecarbonitrile, 5-(5-chloro-1H-benzimidazol-1-yl)-3-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 862813-02-3 CAPLUS
CN 2-Thiophenecarbonitrile, 3-[(2,6-difluorophenyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 862813-04-5 CAPLUS
CN 2-Thiophenecarbonitrile, 5-[5-(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]-3-[(2-(trifluoromethyl)phenyl)methoxy]- (CA INDEX NAME)



RN 862813-06-7 CAPLUS
CN 2-Thiophenecarbonitrile, 3-[(3-bromo-4-pyridinyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 862813-08-9 CAPLUS
CN 2-Thiophenecarbonitrile, 3-(cyclohexylmethoxy)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 862813-10-3 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 1-[5-cyano-4-[[2-(trifluoromethyl)phenyl]methoxy]-2-thienyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 862813-12-5 CAPLUS


CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-14-7 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-phenylethoxy)- (9CI) (CA INDEX NAME)




RN 862813-18-1 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(2-oxo-1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 862813-19-2 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)




RN 862813-20-5 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(tetrahydro-2H-pyran-2-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 862813-15-8 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethoxy)phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 862813-16-9 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-methoxyphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 862813-17-0 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 862813-21-6 CAPLUS


CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)



RN 862813-22-7 CAPLUS


CN 2-Thiophenecarbonitrile, 3-[(1S)-1-(2-chlorophenyl)butoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-23-8 CAPLUS

CN 2-Thiophenecarbonitrile, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(3-thienylmethoxy)- (9CI) (CA INDEX NAME)




RN 862813-24-9 CAPLUS
CN 2-Thiophenecarbonitrile, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-thienylmethoxy))- (9CI) (CA INDEX NAME)




RN 862813-25-0 CAPLUS
CN 2-Thiophenecarbonitrile, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((1R)-1-methylpropoxy))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 660868-28-0 660869-36-0 660869-91-7
660869-17-0 660869-34-1 660869-42-1
660869-46-5 660869-47-6 660869-48-7
660869-49-8 660869-55-6 862813-26-1
862813-28-3 862813-29-4 862813-30-7
862813-31-8 862813-32-9 862813-33-0
862813-34-1 862813-35-2 862813-36-3
862813-37-4 862813-38-5 862813-39-6
862813-40-2 862813-41-0 862813-42-1


862813-43-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzimidazolyl substituted thiophene derivs. with activity against IKK3)
RN 660868-28-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-((1H-benzimidazol-1-yl)-3-[(2-methylphenyl)methoxy])- (9CI) (CA INDEX NAME)




RN 660868-36-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-((1H-benzimidazol-1-yl)-3-(phenylmethoxy))- (9CI) (CA INDEX NAME)




RN 660868-91-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethyl)phenyl)methoxy])- (CA INDEX NAME)




RN 660869-17-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-((5-chloro-1H-benzimidazol-1-yl)-3-(phenylmethoxy))- (9CI) (CA INDEX NAME)




RN 660869-34-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(methylsulfonyl)phenyl)methoxy])- (9CI) (CA INDEX NAME)




RN 660869-42-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethoxy)phenyl)methoxy])- (9CI) (CA INDEX NAME)




RN 660869-46-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-(cyclohexylmethoxy)-5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethoxy)phenyl)methoxy])- (9CI) (CA INDEX NAME)




RN 660869-47-6 CAPLUS
CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(trifluoromethoxy)phenyl)methoxy])- (9CI) (CA INDEX NAME)



RN 660869-48-7 CAPLUS
CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-(4-morpholinyl)ethoxy))- (9CI) (CA INDEX NAME)




RN 660869-49-8 CAPLUS
CN 2-Thiophenecarboxamide, 5-((5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(2-phenylethoxy))- (9CI) (CA INDEX NAME)




RN 660869-55-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(3-bromo-4-pyridinyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 862813-26-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(4-hydroxymethyl)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 862813-28-3 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-29-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1-methyl-1H-benzotriazol-6-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 862813-30-7 CAPLUS

CN 2-Thiophenecarboxamide, 5-[6-methoxy-5-[2-(4-morpholinyl)ethoxy]-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 862813-31-8 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(2,5-difluorophenyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 862813-32-9 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(2,6-difluorophenyl)methoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 862813-33-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5-(3-hydroxypropoxy)-6-methoxy-1H-benzimidazol-1-yl]-3-[[2-(trifluoromethyl)phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 862813-34-1 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 1-[5-(aminocarbonyl)-4-[[2-(trifluoromethyl)phenyl]methoxy]-2-thienyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 862813-35-2 CAPLUS


CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-36-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[5,6-dimethoxy-1H-benzimidazol-1-yl]-3-[(2-methoxyphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 862813-37-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[2-(2-oxo-1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 862813-38-5 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-((tetrahydro-2-furanyl)methoxy)- (CA INDEX NAME)



RN 862813-39-6 CAPLUS


CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)



RN 862813-40-9 CAPLUS


CN 2-Thiophenecarboxamide, 3-[(18)-(1-(2-chlorophenyl)butoxyl)-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862813-41-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(3-thienylmethoxy)- (9CI) (CA INDEX NAME)



RN 862813-42-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-(2-thienylmethoxy)- (9CI) (CA INDEX NAME)



RN 862813-43-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-3-[(1R)-1-methylpropoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 11 OF 33 CAPLUS COPYRIGHT 2007 ACS on STM

AN 2005:371254 CAPLUS Full-text

DN 142:430276

TI Process for preparing thienylbenzimidazoles from benzimidazoles and 2-chloro-3-oxo-2,3-dihydrothiophene-2-carboxylates.

IN Cheung, Mui, Emmite, Kyle Allen

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 85 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI MO 2005037827	A1	20050428	MO 2004-US33585	20041012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1685128	A1	20060802	EP 2004-794836	20041012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, WC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007509070	T	20070412	JP 2006-535584	20041012
US 2007060576	A1	20070315	US 2006-575210	20060410
PRAI US 2003-511991P	P	20031016		
WO 2004-US33585	W	20041012		
OS CASREACT 142:430276; MARPAT 142:430276				
GI				



AB Title compds. [I; R1 = H, alkyl, alkenyl, alkynyl, COR7, CO2R7, cyano, (substituted) heterocyclyl, etc.; Q1 = (R2)a(Y1)b(R2)cR3; a, b, c, aa, bb, cc = 0, 1; 2l of, a, b = 1; n = 0-4; Q4 = (R2)aa(Y2)bb(R2)ccR4; Y1, Y2 = O, CO, CO2, OSO2, CONR7, etc.; R2 = alkylene, alkenylene, alkynylene; R3, R4 = H, halo, alkyl, alkenyl, alkynyl, COR7, CO2R7, NO2, cyano, N3, etc.; R5 = H, halo, alkyl, cycloalkyl, OR7, NHSO2R7, etc.; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, were prepared by treatment of the corresponding N-unsubstituted benzimidazoles with 2-chloro-3-oxo-2,3-dihydrothiophene-2-carboxylates (II; R10 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, protecting group) in the presence of base. Thus, benzimidazole in CHCl3 was treated with Me 2-chloro-3-oxo-2,3-dihydro-2-thiophenecarboxylate and NaHCO3 followed by stirring for 16 h to give Me 5-(1H-benzimidazol-1-yl)-3-hydroxy-2-thiophenecarboxylate.

IT 113347-85-2P 560870-49-5P 660870-50-3P

850850-12-3P


RL: IMP (Industrial manufacture); SPN (Synthetic preparation); PREP

(Preparation)

(process for preparing thienylbenzimidazoles from benzimidazoles and chlorooxodihydrothiophenecarboxylates)


RN 113387-85-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 660870-49-5 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[6-[(1,1-dimethylethoxy)carbonyl]amino]-1H-benzimidazol-1-yl]-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 660870-50-8 CAPLUS


CN 2-Thiophenecarboxylic acid, 5-[5-[(1,1-dimethylethoxy)carbonyl]amino]-1H-

benzimidazol-1-yl]-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 850850-12-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(5,6-dihydroxy-1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2004:799443 CAPLUS Full-text

DN 141:314324

TI Preparation of bicyclic anilide spirohydantoin CGRP receptor antagonists

IN Bell, Ian M.; Gallicchio, Steven N.; Theberge, Cory R.; Zhang, Xu-Fang;

Stump, Craig; Zartman, C. Blair

PA Merck & Co. Inc., USA

SO PCT Int. Appl., 120 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082605	A2	20040930	WO 2004-US7289	20040310
WO 2004082605	A3	20041118		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222383	A1	20040930	AU 2004-222383	20040310
CA 2519475	A1	20040930	CA 2004-2519475	20040310

EP 1608627 A2 20051228 EP 2004-719222 20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
JP 2006520383 T 20060907 JP 2006-507033 20040310
US 2006211712 A1 20060921 US 2005-549338 20050913
US 7202251 B2 20070410
PRAI US 2003-455609P P 20030314
US 2003-486642P P 20030711
WO 2004-US7289 A 20040310
OS CASREACT 141:314324; MARPAT 141:314324
GI




AB The title compds. I; B = (un)substituted bicycloheterocycle; A1, A2 = a bond, (un)substituted CH2; R4 = H, alkyl, fluoroalkyl, cycloalkyl, etc.; R51, R52, R53 = H, alkyl, alkoxy, etc.; R6 = H, alkyl, cycloalkyl, etc.; m, n = 1-2] that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache, were prepared E.g., a multi-step synthesis of II, starting from 6-bromo-2-tetralone, was given. The exemplified compds. I had activity as antagonists of the CGRP receptor, generally with a KI or IC50 value of <50µM. The invention is also directed to pharmaceutical compds. comprising the compds. I and the use of these compds. and compns. in the prevention or treatment of such diseases in which CGRP is involved.

IT 767304-28-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of bicyclic anilide spirohydantoin CGRP receptor antagonists)

RN 767304-28-9 CAPLUS


CN 1H-Benzimidazole-1-acetamide, N-(1',3'-dihydro-3-methyl-2,5-dioxospiro[imidazolidine-4,2'-(2H)inden]-5'-yl)-2,3-dihydro-2-oxo-3-(2-thienyl)- (9CI) (CA INDEX NAME)



IT 767304-98-3P 767305-38-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of bicyclic anilide spirohydantoin CGRP receptor antagonists)


RN 767304-98-3 CAPLUS

CN 1H-Benzimidazole-1-acetic acid, 2,3-dihydro-2-oxo-3-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 767305-38-4 CAPLUS

CN 1H-Benzimidazole-1-acetic acid, 2,3-dihydro-2-oxo-3-(2-thienyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2004:2863 CAPLUS Full-text

DN 140:77149

TI Preparation of benzimidazoles as estrogen agonists/antagonists

IN Chesworth, Richard; Gegnas, Laura Dianne

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2004000817 A2 20031231 WO 2003-1B2670 20030612
WO 2004000817 A3 20040521

M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004002524 A1 20040101 US 2003-460565 20030611
CA 2487266 A1 20031231 CA 2003-2487266 20030612
AU 2003238597 A1 20040106 AU 2003-238597 20030612
BR 2003012069 A 20050329 BR 2003-12069 20030612
EP 1517897 A2 20050330 EP 2003-732945 20030612

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005534675 T 20051117 JP 2004-515164 20030612
MX 2004PA11123 A 20050214 MX 2004-PA11123 20041109

PRAI US 2002-391337P P 20020624
WO 2003-1B2670 W 20030612

OS MARPAT 140:77149
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1, R2 = independently (un)substituted alkyl, Ph, heteroaryl, cycloalkyl, cycloalkenyl, (un)substituted 4-hydroxyphenyl; R3, R4, R5, R6 = independently H, OH, alkyl, alkoxy, halo; with the proviso that at least one of R1 or R2 must be (un)substituted 4-hydroxyphenyl]; their prodrugs, pharmaceutical acceptable salts, or stereoisomeric mixtures of I, prodrug or salt] were prepared as estrogen agonists and/or antagonists for treating estrogen receptor-mediated diseases (no data). For example, II was prepared in 5 steps via cyclocondensation of III (preparation given) in AcOH at 80° overnight to the corresponding methoxyphenylbenzimidazole followed by deprotection. Selected I are selective for the ERβ receptor (no data).


IT 639523-96-9P, 4-[1-(Thiophen-3-yl)-1H-benzimidazol-2-yl]phenol
639523-98-1P, 4-[1-(Thiophen-2-yl)-1H-benzimidazol-2-yl]phenol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(estrogen agonist/antagonist; preparation of benzimidazoles as estrogen agonists/antagonists)

RN 639523-96-9 CAPLUS

CN Phenol, 4-[1-(3-thienyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 639523-98-1 CAPLUS
CN Phenol, 4-[1-(2-thienyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




IT 639523-97-0P, 2-(4-Methoxyphenyl)-1-thiophen-3-yl-1H-benzimidazole
639523-99-2P, 2-(4-Methoxyphenyl)-1-thiophen-2-yl-1H-benzimidazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of benzimidazoles as estrogen
agonists/antagonists)


RN 639523-97-0 CAPLUS
CN 1H-Benzimidazole, 2-(4-methoxyphenyl)-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 639523-99-2 CAPLUS
CN 1H-Benzimidazole, 2-(4-methoxyphenyl)-1-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 544692-81-1 CAPLUS
CN Methanone, 4-(1H-benzimidazol-1-yl)-3-methyl-5-(phenylamino)-2-thienylphenyl- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 2002:849613 CAPLUS Full-text

DN 137:353066

TI Preparation of nitrogenous fused-ring compound having pyrazolyl group as substituents as inhibitors of activation of signal transduction and activation of transcription (STAT6) protein

IN Yoshida, Ichiro; Yoneda, Naoki; Ohashi, Yoshiaki; Suzuki, Shuichi; Miyamoto, Mitsunori; Miyazaki, Futoshi; Seshimo, Hidenori; Kamata, Junichi; Takase, Yasutaka; Shirato, Manabu; Shimokubo, Daiya; Sakuma, Yoshinori; Yokohama, Hiromitsu

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 1006 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

PAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088107	A1	20021107	WO 2002-34156	20020425
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RN:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, EE, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, SF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
AU 2002253596	A1	20021111	AU 2002-253596	20020425
EP 1382603	A1	20040121	EP 2002-722791	20020425
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			



L5 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 2003:195536 CAPLUS Full-text

DN 139:52841

TI N-azolylmethyl ketones as building blocks in heterocyclic synthesis: Synthesis of new polyfunctionally substituted azolylarylazophenols, azolylpyridones and azolylthiophenes

AU Al-Saleh, Balkis; Abdelkhalik, Mervat Mohammed; El-Asasery, Morsy Ahmed; Elnagdi, Mohammed Hilmy

CS Department of Chemistry, Faculty of Science, University of Kuwait, Safat, 13060, Kuwait

SO Journal of Heterocyclic Chemistry (2003), 40(1), 171-175

CODEN: JHTCAD; ISSN: 0022-152X

PB HeteroCorporation

DT Journal

LA English

OS CASREACT 139:52841

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. reacted with 2-arylhydrazonopropanals to yield polyfunctionally substituted azolylarylazophenols. e.g. I and II. The reaction of 1-(1H-benzimidazol-1-yl)-2-propanone and 1-(1H-1,2,4-triazol-1-yl)-2-propanone with phenylisothiocyanate in the presence of α -haloketones afforded the azolylthiophenes III (R = Me, Ph) and IV (R = Me, Ph). The reaction of V with α -haloketone afforded 5-benzotriazol-1-yl-6-methyl-2-(2-oxopropylsulfanyl)nicotinonitrile VI that was utilized as building blocks for the synthesis of condensed pyridines. Compound VI was condensed with DMF dimethylacetal to yield thieno[2,3-b]pyridin-3-yl-N,N-dimethylformamide derivative VII. This was further cyclized with sodium hydride to 1H-thieno[2,3-b]-4,5-b'dipyridin-4-one derivative VIII.


IT 544692-67-3P 544692-81-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of new polyfunctionally substituted azolylarylazophenols, azolylpyridones and azolylthiophenes using N-azolylmethyl ketones as building blocks)

RN 544692-67-3 CAPLUS

CN Ethanone, 1-[4-(1H-benzimidazol-1-yl)-3-methyl-5-(phenylamino)-2-thienyl]- (9CI) (CA INDEX NAME)

US 7074801 B1 20060711 US 2003-475585 20031023
PRAI JP 2001-129959 A 20010426
WO 2002-34156 W 20020425
OS MARPAT 137:353066
GI




AB The 4-(N-containing fused aromatic heterocyclyl)pyrazoles (I) or salts thereof, or hydrates of either (X = a nitrogenous fused aromatic heterocyclic group, e.g., imidazo[1,2-a]pyridine, having (R4)n as a substituent, wherein n = an integer of 0-3; R4 = H, halo, cyano, OH, NH2, C1-6 alkyl, halo-C1-6 alkyl, C2-6 alkenyl, C1-6 alkylsulfonfyl, C1-6 alkylsulfonfylamino, C1-6 alkylsulfonfyl, N-mono, or N,N-di(C1-6 alkyl)amino, C1-6 alkoxy, C1-6 alkylsulfanyl, CONH2, etc.; Y = C3-8 cycloalkyl, C4-8 cycloalkenyl, 5- to 14-membered nonarom. or aromatic heterocyclyl, C6-14 aromatic hydrocarbyl, benzene- or 5- or 6-membered aromatic heterocycle-fused 5- to 7-membered nonarom. ring group; Z = H, NH2, halo, HO, NO2, cyano, N3, CHO, HONH, SO2NH2, guanidino, oxo, C2-6 alkenyl, C1-6 alkoxy, etc.; R1 = H, halo, HO, NO2, cyano, halo-C1-6 alkyl, hydroxy- or cyano-C1-6 alkyl, C2-6 alkenyl, etc.; R2 = H, pyrazolyl; R3 = H, halo, cyano, NH2, C1-4 alkyl, halo-C1-4 alkyl) are prepared. These compds. are inhibitors of STAT6 protein activation and IL-4 and/or IL-13 signal transduction and are useful for prevention and/or treatment of diseases on which the inhibition of STAT6 activation and/or IL-4 and/or IL-13 signal transduction is effective. The diseases include allergy, allergic rhinitis, bronchial asthma, atopic dermatitis, pollinosis, digestive tract allergy, urticaria, hypersensitivity pneumonia, lung aspergillosis, eosinophil leukemia, parasite infection, eosinophilia, eosinophil pneumonia, eosinophil gastroenteritis, autoimmune disease, systemic lupus erythematosus, virus infection, bacteria infection, obesity, overeating (hyperphagia), malignant tumor, and acquired immunodeficiency syndrome (AIDS). Thus, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile was coupled with 6-[3-(4-fluorophenyl)-1-trityl-1H-pyrazolyl]-3-iodoimidazo[1,2-a]pyridine in the presence of tetrakis(triphenylphosphine)palladium and K3PO4 in DMF at 75° for 3 h followed by treating a solution of the coupling product in THF and MeOH with 5 N aqueous HCl to give 4-[6-[3-(4-fluorophenyl)-1H-4-pyrazolyl]imidazo[1,2-a]pyridin-3-yl]benzonitrile dihydrochloride (II). II showed IC50 of <10 nM for inhibiting the IL-4-induced induction of alkali phosphatase in human embryonic kidney cell transfected with STAT gene and STAT reporter gene.

IT 474695-81-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USBS (Uses)


(preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as

preventives and/or remedies of diseases)
 RN 474695-81-3 CAPLUS
 CN 1H-Benzimidazole, -[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-[5-(methylsulfonyl)-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 474711-95-8 474711-96-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)
 RN 474711-95-8 CAPLUS
 CN 1H-Benzimidazole, 6-bromo-1-[5-(methylsulfonyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 474711-86-9 CAPLUS
 CN 1H-Benzimidazole, 5-bromo-1-[5-(methylsulfonyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD


ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L5 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 2002.716272 CAPLUS Full-text
 DN 137.232656
 TI Preparation of 5-(phenylheteroaryl)-1,3-dihydro-2-benzimidazolone MAP kinase inhibitors as anti-inflammatory agents
 IN Dombrowski, Mark Anthony; Letavic, Michael Anthony; McClure, Kim Francis
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 272 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002072576	A1	20020919	WO 2002-IB334	20020130
N:	AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, NG, TD, TG			
CA 2440211	A1	20020919	CA 2002-2440211	20020130
AU 2002226639	A1	20020924	AU 2002-226639	20020130
EP 1370557	A1	20031217	EP 2002-716257	20020130
EP 1370557	B1	20051116		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002007957	A	20040225	BR 2002-7957	20020130
JP 2004526727	T	20040902	JP 2002-571492	20020130
AT 309997	T	20051215	AT 2002-716257	20020130
ES 2251582	T3	20060501	ES 2002-2716257	20020130
US 2003092749	A1	20030515	US 2002-94717	20020131
US 7056918	B2	20060606		
MX 2003PA08142	A	20031212	MX 2003-PA8142	20030909
PRAI US 2001-274791P	P	20010309		
WO 2002-IB334	W	20020130		
OS CASREACT 137:232656; MARPAT 137:232656				
GI				



AB Title compds. I (wherein Het = (un)substituted pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, Ph, heteroaryl, or heterocyclyl; R3 = independently halo, (perhalo)alkyl, (perhalo)cycloalkyl, alkenyl, alkynyl, heterocyclyl(oxy), Ph, OH, (perhalo)alkoxy, OPh, alkylthio, alkyl(amino)sulfonyl, alkylsulfamoyl, carbamoyl, acyl, carboxy, etc.; n = 0-5) were prepared as potent inhibitors of MAP kinases, preferably p38 kinase. For example, (3R)-(-)-1-benzyl-3-aminopyrrolidine was condensed with 1,3-diethyl-2-oxo-2,3-dihydro-1H-benzimidazole-5-carbaldehyde in the presence of MgSO4 in CH2Cl2. Addition of ((4-methylphenyl)sulfonyl)(m-tolyl)methylisocyanide to the 5-(benzylpyrrolidinylmethyl)benzimidazolone using DMF and MP-carbonate gave the 5-(m-tolyl)imidazolyl derivative. Treatment with Pd/C and HCl in MeOH afforded (R)-II-HCl. All of the compds. of the invention that were tested had an IC50 < 10 μM in TNFα and MAPKAP in vitro assays and an ED50 < mg/kg in an in vivo TNFα assay. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion of ischemia in stroke or heart attack, autoimmune diseases, and other disorders (no data).

IT 459194-78-6P, 3-Methyl-1-thiophen-3-yl-5-(5-(m-tolyl)-3H-imidazol-4-yl)-1,3-dihydrobenzimidazol-2-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (anti-inflammatory agent; preparation of (phenylheteroaryl)benzimidazolone MAP kinase inhibitors as anti-inflammatory agents)
 RN 459194-78-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-3-methyl-5-(5-(3-methylphenyl)-1H-imidazol-4-yl)-1-(3-thienyl)- (9CI) (CA INDEX NAME)




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN
 AN 2001.526062 CAPLUS Full-text
 DN 135.107328
 TI Preparation of 1,2-diarylbenzimidazolealkanoates and analogs for treatment of disorders mediated by microglia activation
 IN Kuhnke, Joachim; Helfbrodt, Wolfgang; Moening, Ursula
 PA Schering-Plough GmbH, Germany
 SO PCT Int. Appl., 141 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001051473	A1	20010719	WO 2001-EP334	20010112
M:	AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, NG, TD, TG			
CA 2396227	A1	20010719	CA 2001-2396227	20010112
BR 2001007628	A	20021008	BR 2001-7628	20010112
EP 1246808	A1	20021009	EP 2001-915133	20010112
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
HU 200204011	A2	20030528	HU 2002-4011	20010112
JP 2003523961	T	20030812	JP 2001-551855	20010112
EE 200200390	A	20031015	EE 2002-390	20010112
NZ 519326	A	20050225	NZ 2001-519326	20010112
AU 782993	B2	20050915	AU 2001-42332	20010112
US 2002006948	A1	20020117	US 2001-759360	20010116
US 7115645	B2	20061003		
IN 2002MN0672	A	20050304	IN 2002-MN672	20020524
MX 2002PA05742	A	20020918	MX 2002-PA5742	20020610
BO 106821	A	20030131	BO 2002-106821	20020613
NO 2002003362	A	20020913	NO 2002-3362	20020712
ZA 2002006470	A	20040219	ZA 2002-6470	20020803
US 2006094770	A1	20060504	US 2005-299135	20051208
US 2006050803	A1	20060914	US 2005-305521	20051216
PRAI DE 2000-10002898	A	20000114		
US 2000-178324P	P	20000127		
WO 2001-EP334	W	20010112		
US 2001-759360	A3	20010116		
OS MARPAT 135.107328				
GI				




AB Title compds. [I; R = ZR1R4; R1,R2 = (un)substituted (hetero)aryl; R3 = H, halo, substituted alkyl, alkoxy, etc.; R4 = CO2H, alkoxycarbonyl, CONH2, SO3H, etc.; Z = O, (alkyl)imino, acylimino; Z1 = (heteroatom-interrupted) alkyl(en)ylene, etc.] were prepared. Thus, I (R1 = R2 = Ph, R3 = H) (II; R = 6-OH) was etherified by BrCH2CO2CHMe3 to give II (R = 6-OCH2CO2CHMe3). Data for biol. activity of I were given.
 IT 350233-60-2P 350233-62-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,2-diarylbenzimidazolealkanoates and analogs for treatment of disorders mediated by microglia activation)
 RN 350233-60-2 CAPLUS
 CN Hexanoic acid, 6-[[2-phenyl-1-(3-thienyl)-1H-benzimidazol-5-yl]oxy]-.

methyl ester (9CI) (CA INDEX NAME)



RN 350233-62-4 CAPLUS

CN Hexanoic acid, 6-([2-phenyl-1-(3-thienyl)-1H-benzimidazol-6-yl]oxy)-, methyl ester (9CI) (CA INDEX NAME)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 18 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:891563 CAPLUS [Full-text](#)

DN 134:42130

TI Benzimidazole derivatives as tyrosine kinase inhibitors

IN Bilodeau, Mark T.; Cunningham, April M.; Hungate, Randall W.; Koester, Timothy J.

PA Merck & Co., Inc., USA

SO U.S., 21 pp., Cont.-in-part of U.S. Ser. No. 143,881, abandoned.


CODEN: USXXAM

DT Patent

LA English

FAM.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6162804	A	20001219	US 1999-266331	19990311
PRAI US 1997-60151P	P	19970928		
US 1998-143881	B2	19980831		
OS MARPAT 134:42130				
GI				



AB Benzimidazoles I [X = CH, N; R1 = (un)substituted Ph, thienyl, thiazolyl; R2, R3 = H, alkyl, aryl, cycloalkyl, OH, NO2, NH2, halo; R4 = (un)substituted Ph, pyridinyl, pyrimidinyl, etc.; R5 = H, alkyl, alkoxy, aryloxy, halo, NH2, NO2, etc.] were prepared as tyrosine kinase inhibitors. Thus, II was prepared in 6 steps starting from 4-bromo-1-fluoro-2-nitrobenzene and proceeding via 4'-methoxy-3-nitro-N-phenyl-4-biphenylamine. The products were inhibitors of vascular endothelial growth factor (VEGF) and inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values of 150-550 nM.

IT 221636-30-2P 260258-26-2P 260258-27-3P

260258-28-4P 260258-29-5P 260258-30-8P

260258-32-0P 260258-33-1P 260258-42-2P

260258-43-3P 260258-44-4P 260258-45-5P

260258-46-6P 260258-48-8P 260258-49-9P

260258-50-2P 260258-60-4P 260258-61-5P

260258-62-6P 260258-63-7P 260258-64-8P

260258-66-0P 260258-67-1P 260258-77-3P

260258-78-4P 260258-79-5P 260258-82-0P

260258-84-2P 260258-88-6P 260258-89-7P

312959-19-0F 312959-31-2P 312959-32-4P


312959-34-5P 312959-35-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(benzimidazole derivs. as tyrosine kinase inhibitors)


RN 221636-30-2 CAPLUS

CN 1H-Benzimidazole, 5-[4-[3-(1-piperidinyl)propyl]phenyl]-1-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 260258-26-2 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-27-3 CAPLUS

CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-28-4 CAPLUS

CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-29-5 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 260258-30-8 CAPLUS


CN 2(1H)-Pyridinone, 1-[1-(1-methyl-3-piperidinyl)methyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 260258-32-0 CAPLUS


CN 2(1H)-Pyridinone, 1-[2-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)

benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-33-1 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)-2-methylpropyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-42-2 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-43-3 CAPLUS

CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-44-4 CAPLUS


CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-45-5 CAPLUS
CN 2(1H)-Pyridinone, 1-([3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl])-(9CI) (CA INDEX NAME)




RN 260258-46-6 CAPLUS
CN 2(1H)-Pyridinone, 1-([3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl])-(9CI) (CA INDEX NAME)




RN 260258-48-8 CAPLUS
CN 2(1H)-Pyridinone, 1-([3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl])-(9CI) (CA INDEX NAME)




RN 260258-49-9 CAPLUS
CN 2(1H)-Pyridinone, 1-([3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl])-(9CI) (CA INDEX NAME)




RN 260258-50-2 CAPLUS
CN 4-Piperidinecarbonitrile, 1-[2-[2-oxo-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyridinyl]ethyl]-(9CI) (CA INDEX NAME)




RN 260258-60-4 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)




RN 260258-61-5 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(1-piperidinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)




RN 260258-62-6 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)




RN 260258-63-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)




RN 260258-64-8 CAPLUS
CN 2(1H)-Pyrimidinone, 1-([3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl])-(9CI) (CA INDEX NAME)




RN 260258-66-0 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)




RN 260258-67-1 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)-2-methylpropyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)




RN 260258-73-3 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)




RN 260258-78-4 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(1-piperidinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)




RN 260258-79-5 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)




RN 260258-82-0 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]-(9CI) (CA INDEX NAME)




RN 260258-84-2 CAPLUS
CN 2(1H)-Pyrimidinone, 1-([3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl])-(9CI) (CA INDEX NAME)




RN 260258-88-6 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[(2-(dimethylamino)propyl)-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (9CI) (CA INDEX NAME)




RN 260258-89-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[(3-(dimethylamino)-2-methylpropyl)-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]]- (9CI) (CA INDEX NAME)




RN 312959-29-8 CAPLUS
CN 2(1H)-Pyrimidinone, 4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 312959-31-2 CAPLUS
CN 2(1H)-Pyrimidinone, 5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 312959-33-4 CAPLUS
CN 2(1H)-Pyrimidinone, 5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 312959-34-5 CAPLUS
CN 2(1H)-Pyrimidinone, 4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 312959-35-6 CAPLUS
CN 1H-Benzimidazole, 1-(3-thienyl)- (9CI) (CA INDEX NAME)




RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 2000:215999 CAPLUS Full-text
DN 132:258111
TI Benzimidazoles, their preparation, hole-transporting materials, electroluminescent devices, and electrophotographic photoreceptors thereof
IN Ueda, Hideaki; Fujino, Yasumitsu; Furukawa, Keiichi
PA Minolta Camera Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKKXAF
DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2000095766	A	20000404	JP 1998-269595	19980924
PRAI JP 1998-269595		19980924		
OS MARPAT 132:258111				
GI				




AB The benzimidazole compds. are shown as I (A = arylene, heterocyclic ring which may be linked; Ar1, Ar2 = aryl, heterocyclic ring; R1, R2 = H, alkyl, alkoxy, halo) and are prepared by reacting benzimidazoles II (A, R1, R2 = same as above) with halogens Ar1X and Ar2X (Ar1, Ar2 = same as above; X = halo). The hole-transporting materials for the electrophotog. photoreceptors comprise I and show excellent durability. The electroluminescent devices have 21 layer containing I.

IT 262434-77-5

RL: TEM (Technical or engineered material use); USES (Uses)
(preparation of benzimidazole deriva. for hole-transporting materials and electroluminescent devices and electrophotog. photoreceptors thereof)



RN 262434-77-5 CAPLUS

CN 2-Thiophenamine, 5,5'-[oxybis(4,1-phenylene-1H-benzimidazole-2,1-dilyl)]bis(N,N-diphenyl)- (9CI) (CA INDEX NAME)



FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000012089	A1	20000309	WO 1999-US5297	19990311
W: AB, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RM: GH, GM, KE, LS, MM, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2341409	A1	20000309	CA 1999-2341409	19990311
AU 9930789	A1	20000321	AU 1999-30789	19990311
AU 760020	B2	20030508		
EP 1109555	A1	20010627	EP 1999-912408	19990311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002523459	T	20020730	JP 2000-567206	19990311
US 6465484	B1	20021015	US 2001-786004	20010228
PRAI US 1998-143861	A	19980831		
US 1997-60151P	P	19970926		
WO 1999-US5297	W	19990311		
OS MARPAT 132:194377				
GI				



AB The title compds. [I, X = H, CH; R1, R3 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, aryl, etc.; R4, R5 = H, alkyl, cycloalkyl, etc.] which inhibit tyrosine kinase enzymes, and therefore useful in treating tyrosine kinase-dependent diseases/conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals, were prepared E.g., a multi-step synthesis of the benzimidazole II was given. Compds. I inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 of 150-650 nM.

IT 221636-30-3P 221636-34-5P 260258-26-2P
260258-27-3P 260258-28-4P 260258-29-5P
260258-30-6P 260258-31-9P 260258-32-0P
260258-33-1P 260258-34-2P 260258-42-2P
260258-43-3P 260258-44-4P 260258-45-5P

L5 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN

AN 2000:161133 CAPLUS Full-text

DN 132:194377

TI Preparation of benzimidazoles and imidazo[4,5-b]pyridines as novel angiogenesis inhibitors

IN Bilodeau, Mark T.; Hungate, Randall W.; Cunningham, April M.; Koester, Timothy J.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 73 pp.

CODEN: P1XXD2

DT Patent

LA English

10522958


217 of 245

260258-46-6P 260258-47-7P 260258-48-8P
260258-49-9P 260258-50-2P 260258-60-4P
260258-61-5P 260258-62-6P 260258-63-7P
260258-64-8P 260258-65-9P 260258-66-0P
260258-67-1P 260258-68-2P 260258-77-3P
260258-78-4P 260258-79-5P 260258-82-0P
260258-84-2P 260258-86-4P 260258-88-6P
260258-89-7P 260258-90-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazoles and imidazo[4,5-b]pyridines as novel angiogenesis inhibitors)


RN 221636-30-2 CAPLUS

CN 1H-Benzimidazole, 5-[4-[3-(1-piperidinyl)propyl]phenyl]-1-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 221636-34-6 CAPLUS

CN 1H-Benzimidazole, 5-[6-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 260258-26-2 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-27-3 CAPLUS

CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)

10522958


219 of 245

benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-33-1 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)-2-methylpropyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-34-2 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[2-[2-oxo-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 260258-42-2 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-43-3 CAPLUS

CN 2(1H)-Pyridinone, 1-[2-(1-piperidinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




10522958

218 of 245




RN 260258-28-4 CAPLUS

CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-29-5 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-30-8 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(1-methyl-3-piperidinyl)methyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 260258-31-9 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(4-methyl-1-piperazinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-32-0 CAPLUS

CN 2(1H)-Pyridinone, 1-[2-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-


10522958

220 of 245




RN 260258-44-4 CAPLUS

CN 2(1H)-Pyridinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-45-5 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-46-6 CAPLUS

CN 2(1H)-Pyridinone, 1-[3-(1-methyl-3-piperidinyl)methyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-47-7 CAPLUS


CN 2(1H)-Pyridinone, 1-[3-(4-methyl-1-piperazinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-48-8 CAPLUS
CN 2(1H)-Pyridinone, 1-[2-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-49-9 CAPLUS
CN 2(1H)-Pyridinone, 1-[3-(dimethylamino)-2-methylpropyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-50-2 CAPLUS
CN 4-Piperidinecarbonitrile, 1-[2-[2-oxo-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 260258-60-4 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(1-piperidinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-61-5 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(1-piperidinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-66-0 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-67-1 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)-2-methylpropyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-68-2 CAPLUS
CN 4-Piperidinecarbonitrile, 1-[2-[2-oxo-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyrimidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 260258-77-3 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(1-piperidinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-62-6 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinyl)ethyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-63-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-64-8 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[(1-methyl-3-piperidinyl)methyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-65-9 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(4-methyl-1-piperazinyl)propyl]-5-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-78-4 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(1-piperidinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-79-5 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(4-morpholinyl)ethyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-82-0 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-84-2 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[(1-methyl-3-piperidinyl)methyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-86-4 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(4-methyl-1-piperazinyl)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 260258-88-6 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[2-(dimethylamino)propyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 260258-89-7 CAPLUS
CN 2(1H)-Pyrimidinone, 1-[3-(dimethylamino)-2-methylpropyl]-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 260258-90-0 CAPLUS
CN 4-Piperidinecarbonitrile, 1-[2-(2-oxo-4-[1-(3-thienyl)-1H-benzimidazol-5-yl]-1(2H)-pyrimidinyl)ethyl]- (9CI) (CA INDEX NAME)


BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-phenylbenzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation)

RN 250691-87-3 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-1-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

RN 250691-88-4 CAPLUS
CN 1H-Benzimidazole, 5-methoxy-1-(3-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 22 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:233907 CAPLUS [Full-text](#)
DN 130:252359

TI Preparation of benzimidazoles and imidazopyridines as tyrosine kinase inhibitors
IN Bloudeau, Mark T.; Hungate, Randall W.; Cunningham, April M.; Koester, Timothy J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DT Patent
LA English

PAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9316755	A1	19990408	WO 1998-US19789	19980922
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 21 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:748315 CAPLUS [Full-text](#)
DN 131:351330

TI Preparation of 1-phenylbenzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
IN Boschelli, Diane Harris; Denny, William Alexander; Doherty, Annette Marian; Hamby, James Marino; Khatana, Sonya Shah; Kramer, James Bernard; Palmer, Brian Desmond; Showalter, Howard Daniel Hollis
PA Warner-Lambert Company, USA
SO U.S., 25 pp.
CODEN: USXXAM

DT Patent
LA English

PAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5990146	A	19991123	US 1998-135470	19980817
US 6218388	B1	20010417	US 1999-459011	19991210
PRAI US 1997-56609P	P	19970820		
US 1998-135470	A3	19980817		
US 1999-408630	A3	19990930		
OS MARPAT 131:351330				
GI				



AB The title compds. [I; Ar = (un)substituted aryl; R1-R4 = H, alkyl, halo, etc.] and their pharmaceutically acceptable salts, inhibitors of protein tyrosine kinases such as FGFR and PDGFR which are useful in treating cellular proliferation, especially in treating cancer, atherosclerosis, restenosis, and psoriasis, were prepared. Thus, reduction of 1-(4-nitrophenyl)benzimidazole over Raney Ni in THF afforded 79% I.2HCl (Ar = 4-H2NOC6H4; R1-R4 = H) which showed IC50 of > 10 μM against PDGF-stimulated receptor autophosphorylation in rat aorta smooth muscle cells.

IT 250691-87-3P 250691-88-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


CA 2303830	A1	19990408	CA 1998-2303830	19980922
AU 9895003	A	19990423	AU 1998-95003	19980922
AU 744939	B2	20020307		
EP 1017682	A1	20000712	EP 1998-948427	19980922
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
JP 2001518470	T	20011016	JP 2000-513841	19980922
PRAI US 1997-60151P	P	19970926		
GB 1998-10544	A	19980515		
WO 1998-US19789	W	19980922		
OS MARPAT 130:252359				
GI				




AB The title compds. I [X = N, C; R1 = H, alkyl, cycloalkyl, halo, etc.; R2, R3 = H, alkyl, aryl, OH, etc.; R4 = H, alkyl, alkoxy, alkenyl, etc.; R5 = H, alkyl, halo, etc.], which inhibit tyrosine kinase enzymes, were prepared E.g., 1-phenyl-5-(4-methoxyphenyl)benzimidazole was prepared

IT 221636-30-2P 221636-34-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazoles and imidazopyridines as tyrosine kinase inhibitors)

RN 221636-30-2 CAPLUS
CN 1H-Benzimidazole, 5-[4-[3-(1-piperidinyl)propyl]phenyl]-1-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 221636-34-6 CAPLUS
CN 1H-Benzimidazole, 5-[6-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]-1-(3-thienyl)- (9CI) (CA INDEX NAME)




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 1998:789290 CAPLUS [Full-text](#)
DN 130:177118
TI Structure-activity relationships for 1-phenylbenzimidazoles as selective
ATP site inhibitors of the platelet-derived growth factor receptor
AU Palmer, Brian D.; Sami, Jeff B.; Boyd, Maruta; Boschelli, Dianne H.;
Doherty, Annette M.; Hamby, James M.; Khatana, Sonya S.; Kramer, James B.;
Kraker, Alan J.; Panek, Robert L.; Lu, Gina H.; Dahring, Tawny K.;
Winters, R. Thomas; Showalter, H. D. Hollis; Denny, William A.
CS Auckland Cancer Society Research Centre Faculty of Medicine and Health
Sciences, The University of Auckland School of Medicine, Auckland, N. Z.
SO Journal of Medicinal Chemistry (1998), 41(27), 5457-5465
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB 1-Phenylbenzimidazoles are shown to be a new class of ATP-site inhibitors of
the platelet-derived growth factor receptor (PDGFR). Structure-activity
relationships (SARs) are narrow, with closely related heterocycles being
inactive. A systematic study of substituted 1-phenylbenzimidazoles showed
clear SARs. Substituents at the 4'- and 3'-positions of the Ph ring are
tolerated but do not significantly improve activity, while substituents at the
2'-position abolish it. Substituents in the 2-, 4-, and 7-positions of the
benzimidazole ring (with the exception of 4-OH) also abolish activity. Most
substituents at the 5- and 6-positions maintain or increase activity, with the
5-OH, 5-OMe, 5-COMe, and 5-CO₂Me analogs being >10-fold more potent than the
parent 1-phenylbenzimidazole. The 5-OMe analog was both the most potent
inhibitor, and showed the highest selectivity (50-fold) between PDGFR and FGFR
isolated enzymes, and also a moderately effective inhibitor (IC₅₀ = 1.9 μM) of
PDGF-stimulated PDGFR autophosphorylation in rat aorta smooth muscle cells.
IT 220495-91-0P 220495-92-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(structure-activity relationships for 1-phenylbenzimidazoles as
selective ATP site inhibitors of the platelet-derived growth factor
receptor)
RN 220495-91-0 CAPLUS
CN 1H-Benzimidazole, 4-methoxy-1-(2-thienyl)-, monohydrochloride (9CI) (CA
INDEX NAME)




● HCl


RN 220495-92-1 CAPLUS
CN 1H-Benzimidazole, 4-methoxy-1-(3-thienyl)-, monohydrochloride (9CI) (CA
INDEX NAME)



L5 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 1988:562796 CAPLUS [Full-text](#)
DN 109:162796
TI Determination of telenezepine in human serum by gas chromatography-mass
spectrometry
AU Sturm, E.; Junker, A.
CS Byk Gulden Pharm., Konstanz, D-7750, Fed. Rep. Ger.
SO Journal of Chromatography (1988), 430(1), 43-51
CODEN: JOCRAM; ISSN: 0021-9673
DT Journal
LA English
OS CASREACT 109:162796
AB A method for determining telenezepine in human serum is described. Analytes
are obtained from alkalized serum by extraction of the drug using reversed-
phase octadecylsilane-bonded silica cartridges. Telenezepine and a demethyl
analog added to serum as internal standard are retained on the C18 cartridge
and recovered by elution with MeOH. The gas chromatog. properties of
telenezepine and the internal standard are improved by a 2-step derivatization
involving a benzodiazepine-benzimidazole rearrangement and simultaneous
formation of a Me ester function. The processed extract is analyzed by gas
chromatog.-mass spectrometry with selected-ion monitoring. Quantification is
linear over the range 2-40 ng/mL. Inter-day precision is within 7%, except at the
anal. is limited by the extensive sample pretreatment essential for
derivatization of telenezepine.
IT 117019-16-6P 117019-17-7P 117019-18-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for telenezepine determination in human blood by gas
chromatog.)
RN 117019-16-6 CAPLUS
CN 3-Thiophenecarboxylic acid, 5-methyl-4-[(4-methyl-1-piperazinyl)methyl]-1H-
benzimidazol-1-yl]-, methyl ester (9CI) (CA INDEX NAME)



INDEX NAME)



● HCl


RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 1989:85382 CAPLUS [Full-text](#)
DN 110:85382
TI Electrophotographic photoreceptor containing charge-transporting
benzimidazole derivative
IN Shiino, Yasuko; Matsumoto, Masakazu
PA Canon K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKKXAP
DT Patent
LA Japanese
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI JP 63157157 A 19880630 JP 1986-303856 19861222
PRAI JP 1986-303856
GI




AB The title photoreceptor has a photosensitive layer containing a benzimidazole
derivative I (R1 = alkyl, aryl, heterocyclyl; R2, R3 = H, R1, aralkyl; R2, R3,
and the central C may form a ring residue; A = aralkyl, R1).
IT 119028-39-6
RL: TEM (Technical or engineered material use); USES (Uses)
(electrophotog. charge-transporting agent)
RN 119028-39-6 CAPLUS
CN Benzenamine, N,N-dimethyl-4-[1-(2-thienyl)-5-(9H-xanthen-9-ylidenemethyl)-
1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)


RN 117019-17-7 CAPLUS
CN 3-Thiophenecarboxylic acid, 4-[2-[(4-methyl-1-piperazinyl)methyl]-1H-
benzimidazol-1-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 117019-18-8 CAPLUS
CN 3-Thiophenecarboxylic acid, 5-methyl-4-[(4-methyl-1-piperazinyl)methyl]-
1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 1988:150195 CAPLUS [Full-text](#)
DN 108:150195
TI Reactions of methyl 3-hydroxythiophene-2-carboxylate. Part 4. Synthesis
of methyl 5-azoly-3-hydroxythiophene-2-carboxylates
AU Corral, Carlos; El-Ahawy, Mahmoud B.; Lissavetzky, Jaime; Manzaneres,
Ignacio
CS Inst. Quim. Med., CSIC, Madrid, 28006, Spain
SO Journal of Heterocyclic Chemistry (1987), 24(5), 1301-3
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 108:150195
GI




AB Oxodihydrothienopyranes I (R1 = H, Cl) were treated with heterocycles, e.g., pyrazole, imidazole, benzotriazole) to give thienopyranes II (R2 = 1-pyrazolyl, 1-imidazolyl, 1-benzotriazolyl, etc.).

IT 113387-85-2P 113387-86-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 113387-85-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 113387-86-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-4-chloro-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



LS ANSWER 27 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1988:131570 CAPLUS [Full-text](#)

DN 108:131570

TI Process for the preparation of 3-hydroxy-5-(1-polyazolyl)-2-methoxycarbonylthiophenes, useful as pharmaceuticals or their intermediates

IN Corral Saleta, Carlos; Lissavetzky Diez, Jaime

PA Consejo Superior de Investigaciones Científicas, Spain

SO Span., 7 pp.

CODEN: SPXXAD


DT Patent

LA Spanish

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 547442	A1	19861116	ES 1985-547442	19850930
PRAI ES 1985-547442		19850930		

GI




AB The title compds. (I; X = H, halo, R = heterocyclic polyazolo or benzopolyazolo), useful as intermediate or final products in the synthesis of new therapeutic agents (no data), are prepared by condensation with chloro(methoxycarbonyl)oxodihydrothiophenes II with 2 equivalent polyazolo or benzopolyazolo RH at room temperature. A solution of 0.009 mol II (X = H) in HClO4 was treated with 0.018 mol pyrazole and kept at room temperature for 2 days to give crystalline I (X = H, R = 1-pyrazolyl).

IT 113387-85-2P 113387-86-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as drug and/or intermediate)


RN 113387-85-2 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-3-hydroxy-, methyl ester (CA INDEX NAME)



RN 113387-86-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 5-(1H-benzimidazol-1-yl)-4-chloro-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



LS ANSWER 28 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1986:198778 CAPLUS [Full-text](#)

DN 104:198778

TI Synthesis, structure, and interconversion of polypyrazolylborate complexes of molybdenum(V)

AU Lincoln, Sandra; Koch, Stephen A.

CS Dep. Phys. Life Sci., Univ. Portland, Portland, OR, 97203, USA

SO Inorganic Chemistry (1986), 25(10), 1594-602

CODEN: INOCAJ; ISSN: 0020-1669

DT Journal

LA English

AB HB(pz)3MoOCl2 (I; pz = pyrazolyl) was prepared by the reaction of O2 with HB(pz)3MoCl3. Two (HB(pz)3MoOCl2)2O (II) geometric isomers and (HB(pz)3)2Mo2O2(μ-O)2 (III) were obtained from the reaction of MoCl5 and KHB(pz)3 in dilute HCl. Mo4(HB(pz)3)2(O)4(μ-O)4(μ-OMe)2(HOMe)2 (IV) was prepared from the reaction of III with MeOH. I, II, and IV were structurally characterized by x-ray diffraction. II have the structures typical of Mo2O34 dimers with linear Mo-O-Mo bridges; they provide the 1st example of Mo-Mo distortional isomers with a d1 electronic configuration: the Mo-oxo distance of 1.670(4) and 1.779(6) Å. The yellow-brown colors of II with intense bands at 21,045 cm⁻¹ indicate that the previous interpretations of the electronic spectra of Mo2O34 complexes must be reevaluated. The chemical and crystallog. characterization of IV indicated that it is a Mo(V) tetramer with a zigzag chain of 4 Mo atoms. The importance of correctly distinguishing between a coordinated alkoxide and a coordinated alc. is demonstrated in the structure of IV and by the reformulation of 2 Mo(V) tetramers that had been previously reported in the literature as mixed-valence complexes.

IT 101215-85-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(reformulation of alkoxo complex as)

RN 101315-85-9 CAPLUS


CN Molybdate(2-), tetrachlorobis(ethanol)di-μ-ethoxydi-μ-oxodi-μ3-oxotetraoxotetra-, (2Mo-Mo), stereoisomer, dihydrogen, compd. with 1,2-di-2-thienyl-1H-benzimidazole (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 101315-84-8

CMF C8 H22 Cl4 Mo4 O12 . 2 H

CCI CCS




● 2 H+

CM 2

CRN 101315-83-7

CMF C15 H10 N2 S2



LS ANSWER 29 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1984:156539 CAPLUS [Full-text](#)

DN 100:156539

TI Compounds with antiulcer and antisecretory activity. II.

3-Heteroaryl-benzimidazolin-2-ones

AU Bianchi, Mario; Butti, Alina; Rossi, Silvano; Barzaghi, Fernando; Marcaris, Viviana

CS Dep. Chem. Synth., Roussel-Maestretti S.p.A., Milan, Italy


SO European Journal of Medicinal Chemistry (1983), 18(6), 495-500

CODEN: EJWCA5; ISSN: 0009-4374

DT Journal

LA English

GI




AB Benzimidazolones I (R = H, Me, Et, CHMe2; R1 = (un)substituted pyridyl, pyrazinyl, 2-pyrimidinyl, pyridazinyl, 2-quinolyl, 3-thienyl, 2-thiazolyl, 5-tetrazolyl, 5-methyl-1,2,4-oxadiazol-3-yl; R2 = H, 5-Cl, 6-Cl, 5-CF3) (24 compds.) were prepared by various methods. I (R = Me, R1 = pyrazinyl, R2 = 5-Cl) had the best antisecretory and antiulcer activity, but induced convulsions, vomiting, and diarrhea on repeated oral administration in dogs.

IT 89660-06-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiulcer and antisecretory activity of)


RN 89660-06-0 CAPLUS

CN 2H-Benzimidazol-2-one, 5-chloro-1,3-dihydro-1-methyl-3-(3-thienyl)- (9CI) (CA INDEX NAME)





LS ANSWER 30 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1979:121555 CAPLUS [Full-text](#)
 DN 90:121555
 TI Heteroarene fused benzodiazepines. Part 1. Synthesis of thieno[2,3-b][1,5]-, -[3,2-b][1,5]-, and -[3,4-b][1,5]benzodiazepines
 AU Chakrabarti, Jiban K.; Hicks, Terence A.; Motten, Terrence M.; Tupper, David E.
 CS Lilly Res. Cent. Ltd., Windlesham, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1978), (9), 937-41
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 90:121555
 GI




AB Thienobenzodiazepines I (R = H, F) were prepared by sequential reaction of Et 2-amino-5-ethylthiophene-3-carboxylate with 2,5-F(R)C6H3NO2 II (R = H, F) in the presence of BuLi, catalytic reduction, and cyclization of the resulting amino esters III by 3 equiv NaCH2SOMe (70%, N). Thienobenzodiazepines IV and V were prepared analogously from reactions of Me 3-aminothiophene-2-carboxylate and Me 4-aminothiophene-3-carboxylate, resp., with II. An attempted cyclization of III (R = F) with 1 equiv NaCH2SOMe at 280° gave the rearranged benzimidazolone product VI.


IT 69363-84-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 19763-84-4 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-(5-ethyl-2-thienyl)-5-fluoro-1,3-dihydro- (9CI) (CA INDEX NAME)




LS ANSWER 32 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1975:497232 CAPLUS [Full-text](#)
 DN 83:97232
 TI Synthesis of 4,9-dihydro-9-(2-dimethylaminoethyl)-4-methylthieno[3,4-b][1,5]benzodiazepin-10-one, a dibenzepine-analogous thiophene derivative
 AU Hromatka, Otto; Binder, Dieter; Eichinger, Karl
 CS Inst. Org. Chem., Tech. Hochsch. Wien, Vienna, Austria
 SO Monatshefte fuer Chemie (1975), 106(2), 375-9
 CODEN: MOCMB7; ISSN: 0026-9247
 DT Journal
 LA German
 GI For diagram(s), see printed CA Issue.
 AB Condensation of o-C6H4(NH2)2 with thiophene I in boiling xylene gave 5% thienobenzodiazepinone II and 58% thienylbenzimidazolone III and IV. Decreasing the temperature by use of boiling toluene gave 46% II, but lower temps. did not give better yields. II was aromatized to V (R = R1 = H), which was methylated to V (R = Me, R1 = H) and then treated with Cl(CH2)2NMe2 to give V (R = Me, R1 = (CH2)2NMe2).
 IT 56276-54-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and desulfurization of)
 RN 56276-54-1 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-(2,5-dihydro-3-thienyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



IT 56276-55-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 56276-55-2 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-(4,5-dihydro-3-thienyl)-1,3-dihydro- (9CI) (CA INDEX NAME)




LS ANSWER 31 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1978:37692 CAPLUS [Full-text](#)
 DN 88:37692
 TI Synthesis of nitroheterocycles: Part IV. Syntheses of 1-substituted 4-nitroisquinolines, 5- and 6-nitroindazoles and 6-nitrobenzimidazoles
 AU Arya, V. P.; Fernandes, P.; Honkan, V.; Ray, D. K.; Shrivastava, V. B.
 CS Ciba-Geigy Res. Cent., Bombay, India
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1977), 15B(7), 625-8
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 88:37692
 GI




AB 1-Chloro-4-nitroisquinoline (I) was treated with oxazolidin-2-one and thiazolidin-2-one in the presence of NaH to give II (X = O, S), resp. Reaction of I with H2NCH2CH(OMe)2 gives III which was cyclized to give IV. 5- and 6-nitroindazoles react with 2-halo-3- or 5-substituted-pyridines in the presence of NaH in DMF to yield 1-substituted 5- and 6-nitroindazoles (e.g., V). Similar reaction of 6-nitrobenzimidazole sodium salt with compds. containing reactive chlorine affords 1-substituted-6-nitrobenzimidazoles (e.g., VI). The prepared compds. possess no appreciable in vivo antibacterial, antifungal, antiamoebic or antiparasitic activity.

IT 65092-66-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 65092-66-2 CAPLUS
 CN Thiophene-3-ol, tetrahydro-4-(6-nitro-1H-benzimidazol-1-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


LS ANSWER 33 OF 33 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1975:497128 CAPLUS [Full-text](#)
 DN 83:97128
 TI Synthesis of 1,3-dihydro-3-(2-dimethylaminoethyl)-1-(3-thienyl)benzimidazol-2-ones
 AU Hromatka, Otto; Binder, Dieter; Eichinger, Karl
 CS Inst. Org. Chem., Tech. Hochsch. Wien, Vienna, Austria
 SO Monatshefte fuer Chemie (1975), 106(2), 555-8
 CODEN: MOCMB7; ISSN: 0026-9247
 DT Journal
 LA German
 OS CASREACT 83:97128
 GI For diagram(s), see printed CA Issue.
 AB Benzimidazolone (I, R = H) (III) was prepared by condensation of o-(H2N)2C6H4 with Me tetrahydro-4-oxo-3-thiophenecarboxylate. Amination of II by Cl(CH2)2NMe2 gave I (R = CH2CH2NMe2). Dehydrogenation of I by chloranil gave benzimidazolone (III, R = X = H) which was aminated to give III (R = CH2CH2NMe2, X = H). Addnl. obtained were III (R = H, CH2CH2NMe2, X = Cl).
 IT 56276-54-1P 56276-55-2P 56477-00-0P
 56477-01-1P 56477-02-2P 56477-03-3P
 56477-04-4P 56477-05-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 56276-54-1 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-(2,5-dihydro-3-thienyl)-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 56276-55-2 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-(4,5-dihydro-3-thienyl)-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 56477-00-0 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-(2,5-dihydro-3-thienyl)-3-(2-(dimethylamino)ethyl)-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 56477-01-1 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 56477-02-2 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(2-chloro-3-thienyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 56477-03-3 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[2-(dimethylamino)ethyl]-1,3-dihydro-3-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 56477-04-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(2-chloro-3-thienyl)-3-[2-(dimethylamino)ethyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 56477-05-5 CAPLUS
CN 2H-Benzimidazol-2-one, 1-(2-chloro-3-thienyl)-3-[2-(dimethylamino)ethyl]-1,3-dihydro-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 56477-04-4
CMP C15 H16 Cl N3 O S



CM 2

CRN 88-89-1
CMP C6 H3 N3 O7





=> d 14 bib abs

L4 ANSWER 1'OF 2 CAPLUS COPYRIGHT 2007 ACS ON STN
AN 2004:143141 CAPLUS Full-text
DN 140:199325
TI Preparation of benzimidazolyl substituted thiophenes as Polo like kinases (PLK) inhibitors for treating cancer
IN Andrews, Clarence W., III; Cheung, Mui; Davis-Mard, Ronda G.; Drewry, David Harold; Emmite, Kyle Allen; Hubbard, Robert Dale; Kuntz, Kevin W.; Linn, James Andrew; Mook, Robert Anthony; Smith, Gary Keith; Veal, James Marvin
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 235 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CMT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014899	A1	20040219	WO 2003-US24272	20030804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, ME, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493908	A1	20040219	CA 2003-2493908	20030804
AU 2003265348	A1	20040225	AU 2003-265348	20030804
EP 1546137	A1	20050629	EP 2003-784888	20030804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, BR, HU, SK				
BR 2003013160	A	20050712	BR 2003-13160	20030804
CN 1688576	A	20051026	CN 2003-823755	20030804
JP 2006050522	T	20060216	JP 2004-527723	20030804
NZ 538134	A	20060331	NZ 2003-538134	20030804
RU 2296758	C2	20070410	RU 2005-102390	20030804
ZA 2005000864	A	20060426	ZA 2005-864	20050128
NO 2005000525	A	20050506	NO 2005-525	20050131
US 2006074119	A1	20060406	US 2005-522958	20050131
MX 2005PA01544	A	20050419	MX 2005-PA1544	20050208
IN 2005KN00321	A	20060106	IN 2005-KN321	20050302
PRAI US 2002-402008P	P	20020808		
WO 2003-US24272	W	20030804		
OS MARPAT 140:199325				
GI				



AB The title compds. [I, R1 = H, alkyl, COR7, CO2R7, etc.; Q1 = OCH2Ph, NHCH2Ph (both substituted on Ph ring), etc.; n = 0-4; Q2 = OMe, Cl, Br, etc.; R5 = H, halo, alkyl, etc.; R7 = H, alkyl, cycloalkyl, etc.], useful for treating a condition mediated by PLK, were prepared e.g., a multi-step synthesis of II which showed pIC50 of > 7 in assay for inhibition of PLK1, was given. The pharmaceutical composition comprising the title compds. I is claimed.
RE.CMT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
182.17	354.48
SINCE FILE	TOTAL
ENTRY	SESSION
-26.52	-26.52

FILE 'REGISTRY' ENTERED AT 06:43:08 ON 21 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)
Property values tagged with IC are from the ZIC/VINITI data file provided by Infochem.

STRUCTURE FILE UPDATES: 20 AUG 2007 HIGHEST RN 945102-95-4
DICTIONARY FILE UPDATES: 20 AUG 2007 HIGHEST RN 945102-95-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d his


(FILE 'HOME' ENTERED AT 06:41:03 ON 21 AUG 2007)

FILE 'REGISTRY' ENTERED AT 06:41:09 ON 21 AUG 2007
L1 STRUCTURE UPLOADED
L2 702 S L1 S95 FULL

FILE 'CAPLUS' ENTERED AT 06:41:34 ON 21 AUG 2007
L3 34 S L2
L4 2 S US2001-522958/APPS
L5 33 S L3 NOT L4

FILE 'REGISTRY' ENTERED AT 06:43:08 ON 21 AUG 2007

=> d ll
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> log hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.45	354.93

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-26.52

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 06:43:29 ON 21 AUG 2007